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Linker histone H1 associates with nucleosomes, facilitating folding and 
packaging of DNA into higher order chromatin structure. With 11 variants in 
mammals, histone H1 is the most divergent histone class.  Histone H1 variants are 
differentially expressed during development and cellular differentiation, and regulate 
specific gene expression in vivo. Ample studies have established the role of linker 
histone H1 in chromatin compaction and gene expression regulation; however, its 
role in diseases, such as cancer, remain understudied.   
In this study, we explore the role of H1 in ovarian cancer, one of the most 
devastating gynecological cancers due to its poor prognosis and difficulty in early 
diagnosis. Although mutations of genes responsible for cell proliferation, differentiation 
and survival have been found in ovarian cancers, ample evidence also suggests an 
important role of epigenetic changes in the disease occurrence and progression. 
Because epigenetic changes do not alter DNA sequence and can be reversed or 
reprogrammed, they offer an attractive avenue for therapeutic intervention in cancer 
treatment. 
 Using quantitative RT-PCR assays, we systematically examined the 
expression of 7 H1 genes in 33 human epithelial ovarian tumors.  By clustering 
analysis, we found that ovarian malignant adenocarcinomas and benign adenomas 
exhibited characteristic expression patterns.  We demonstrated that expression 
profiling of 7 H1 genes in tumor samples discriminates adenocarcinomas vs. 
adenomas with high accuracy. These findings indicate that the expression of H1 
variants is exquisitely regulated and may serve as potential epigenetic biomarkers for 
ovarian cancer.  
To further investigate the role of H1 subtypes in ovarian cancer cells, we 
employed an over-expression approach to test the function of H1 subtypes in an ovarian 
cancer cell line, OVCAR-3.  We found that histone H1.3 over-expression significantly 
xvii 
 
suppresses the growth and colony formation of OVCAR-3 cells.  Gene expression arrays 
identified many genes affected by H1.3 over-expression, and oncogene H19 was among 
the genes most dramatically repressed by H1.3 over-expression.  Over-expression of 
several other H1 subtypes did not lead to significant reduction of H19 expression, 
suggesting a specific effect by H1.3.  Consistently, knockdown of H1.3 increased H19 
expression.  Furthermore, increased expression of H1.3 led to accumulation of H1.3 as 
well as increased DNA methylation at the regulatory regions of H19. Finally, we identified 
a synergistic effect of H1.3 over-expression and H19 knockdown on inhibition of ovarian 
cancer cell growth.  These results establish oncogene H19 as a direct target of histone 
H1.3, identify a novel role of H1 variants in ovarian cancer mediated through regulating 
oncogene H19 expression, and may offer new approaches for ovarian cancer 




CHAPTER 1: Introduction 
 
1.1. Role of linker histone in chromatin structure and  dynamics 
 
1.1.1. Chromatin structure and nucleosome particles 
The human genome contains 3 billion base pairs (bp) accommodated in less than 
10 micrometers of cell nucleus. To accomplish this task, DNA must be efficiently 
packaged. At first, 146 bp of double-stranded DNA are wrapped around a histone 
octamer consisting of two molecules of each H2A, H2B, H3 and H4 core histones. 
Together, they form a nucleosome, a fundamental repetitive unit of chromatin that 
can be further folded into high-ordered chromatin structures [1-3]. The DNA fragment 
between nucleosomes, called linker DNA, is bound by linker histone H1 that 
stabilizes higher order chromatin folding.  Histone H1 binds at the entry and exit of 
nucleosomal DNA and linker DNA, forming a chromatosome. The formation of 
chromatosome by nucleosome and linker histone H1 plays an essential role in folding 
a transcriptionally active “beads-on-a-string” structure into a 30 nanometer (nm) 
chromatin fiber [4]. Further compaction in the nucleus includes 100 to 400 nm 
interphase fibers and an even more condensed metaphase chromosome structure.  
 
1.1.2. Core histones 
Core histones are small evolutionarily conserved proteins that assemble into an 
octamer and form the nucleosome core [5]. Each core histone protein consists of a 
globular domain interacting with neighboring histones and an amino terminal tail that 
extends from the nucleosome surface. It was demonstrated that core histone tails are 
fundamental elements required for nucleosomal structure formation [6]. 
Posttranslational modifications, such as acetylation, phosphorylation, 
methylation, ubiquitylation, sumoylation, and ribosylation, frequently occur on lysines 
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(K), arginines (R), serines (S) and threonines (T) of core histone tails.  It has been 
proposed that a combination of different posttranslational modification serves as a 
code for regulating biological functions [7,8]. For instance, in higher Eukaryotes, 
transcriptional repression correlates with tri-methylation of histone H3K9 and a 
simultaneous lack of acetylation on H3 and H4 [9]. By facilitating the recruitment of 
chromatin remodeling complexes and modifying activities, histone marks participate 
and influence the dynamics of transcription and gene expression.       
 
1.1.3. Linker histone H1 
 
1.1.3.1. Histone H1 protein family and its variants  
Linker histone H1 interacts with linker DNA at the dyad axis of the nucleosome at 
the entry and exit sites of the nucleosomal DNA.  Its extended structural functions 
include stabilization, folding and condensation of chromatin into the 30 nm chromatin 
fiber, as well as positioning and spacing between nucleosomes [10-12]. Numerous 
studies have also shown that the linker histone H1 participates in multiple cellular 
processes occurring on the chromatin template, such as gene expression and DNA 
replication and repair [11,13-19].  
Histone H1 belongs to a winged-helix family of DNA-binding proteins. The ratio of 
histone H1 per nucleosome varies between 0.5 in embryonic stem cells (ESC) to 1 or 
more in differentiated tissues [10]. Saccharomyces cerevisiae, Tetrahymena 
thermophile or Ascobolus immerses, contain only one variant of linker histone [20-
22], and deletion of histone H1 leads to up- and down-regulation of specific genes 
and even growth arrest in Ascobolus [18,23,24]. The number of different H1 subtypes 
increases in higher Eukaryotes, with five H1 isoforms in Xenopus laevis and as many 
as 11 variants in mammals [25]. 
Histone H1 is a lysine-rich protein, consisting of a short basic N-terminal tail, a 
highly conserved globular domain, and a long, positively charged C-terminal tail 
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(Figure 1.1A). The central globular domain contains –helix and –sheet structures 
(Figure 1.1B). H1 proteins, especially the tails, are post-translationally modified, 
mostly by phosphorylation, but also by acetylation, methylation, sumoylation, and 
ubiquitination [11,26-28].  Those modifications can often modulate the interactions of 
H1 with chromatin and other proteins.  For instance, histone lysine methyltransferase 
Ezh2, a component of Polycomb Complex 2 complex, methylates histone H1.4 at 
Lys26 [29,30]. Once methylated at K26, H1.4 is specifically recognized by 
chromodomain of HP1, the major heterochromatin protein, which further leads to 
transcriptional repression. In contrast, simultaneous phosphorylation of the 
neighboring Ser27 by cyclin-dependent kinase 2 (CDK2) prevents interaction with 




Figure 1.1: Linker histone H1 structure. A. Schematic representation of histone H1. B. Amino 
acid sequence comparison of histone H1 subtype globular domain. α1-3 represent three 











In mammals, there are five major somatic H1 subtypes (H1.1, H1.2, H1.3, H1.4 
and H1.5) differentially expressed in dividing and non-dividing cells [33-35]. For 
instance, expression of histones H1.1 and H1.5 are low in most of tissue and cell 
types, except in the thymus, spleen and lymphocytes, and further decreases in 
quiescent or differentiated cells [36-38]. Histones H1.2, H1.3 and H1.4 are 
ubiquitously expressed, suggesting their critical role in maintaining cellular functions. 
H1.2 and H1.4 often increases in expression during cell differentiation or quiescence 
[22,33,36,37,39,40]. The replacement subtype H1.0 accumulates in terminally 
differentiated cells. Tissue specific H1 subtypes include testis-specific subtypes such 
as H1t, H1T2, HILS1, oocyte-specific subtype H1oo, and the recently-discovered H1x 
[32,33,41-44].  
The nomenclature of histone H1 subtypes has changed over time and may bring 
confusion; Table 1.1 lists the different names used by scientists for human H1 
subtypes. Most histone H1 subtypes are intronless genes that lack poly-A tails, but 
are terminated by palindromic termination elements. H1oo is the only H1 subtype that 
contains introns and its alternative splicing results in two mRNA forms (alpha and 
beta) [45].  A large cluster of histone H1 is located in chromosome 6 of the human 
genome, and others reside in chromosome 22 (H1.0), chromosome 3 (H1x, H1oo), 














Table 1.1. Overview of common nomenclatures of human linker histone subtypes. 
*Histone H1.2 (HISTH1C) expresses both DNA-replication dependent and independent (poly A+) mRNAs,  
Chr. - chromosome, AA - amino acids. 
 
Transcription of linker histone subtypes can occur during replication dependent or 
independent processes. All somatic H1s and testis-specific H1t are transcribed 
during early or middle S-phase, and sustain their high levels until the end of DNA 








































cluster 1, H1a H1.1 hH1e 





21710 214 6 
HIST1H1C* 
Histone 
cluster 1, H1c H1.2 hH1d 





21233 212 6 
HIST1H1D 
Histone 






22218 220 6 
HIST1H1E 
Histone 
cluster 1, H1e H1.4 hH1b 





21734 218 6 
HIST1H1B 
Histone 
cluster 1, H1b H1.5 hH1a 
H1B   











H1t  H1Ft 
NM_ 
005323 

























H10  H1FV 
NM_ 
005318 





H1oo  osH1 
NM_ 
153833 





H1x   
NM_ 
006026 




















27950 260 17 
6 
 
during S-phase although its protein amount drastically differs from the respective 
RNA levels [46]. Replication-dependent histone genes encode most linker histone 
proteins [47,48]. Instead of poly-A tails, mRNAs of most linker histones contain 3’ 
stem-loop sequences. Among the replication dependent H1s, histone H1.2 is the only 
somatic H1 gene whose mRNA also possesses a poly-A tail for 3' processing signals 
[49].  
Four regulatory mechanisms control the proper amount of histone protein 
accumulation during cell cycle: transcription of histone genes, pre-mRNA processing 
efficiency, half-life of mRNA, and degradation of excessive histone proteins.  
Replication-dependent histones are the most highly cell-cycle-regulated proteins in 
mammalian cells. Replication-independent histone H1 subtypes containing 
polyadenylation signals, such as H1.0, H1x, H1t and H1oo, are not strictly limited to 
particular cell cycle phase (reviewed in [50]).   
Histone H1 variants differ in timing of expression, extent of phosphorylation, 
turnover rate, and chromatin binding affinity [51-57]. Histone H1 proteins are thought 
to be continuously exchanged at chromatin binding sites after being dissociated from 
another binding site. Fluorescence recovery after photobleaching (FRAP) enabled 
the analysis of many linker histone properties in living cells, such as binding 
dynamics to chromatin, exchange rate and recovery time [58,59].  Such studies 
indicated that histone H1 mobility is less rapid than other chromatin binding proteins. 
However, their exchange rate is much higher than core histones [60]. The amount of 
time histone H1 resides at the chromatin binding site depends on the 
posttranslational modifications on its terminal domains and other nuclear proteins 
that compete for particular binding sites [58,61].  
 Many studies have been dedicated to classifying H1 subtypes according to their 
affinity to chromatin and condensation abilities; however, the conclusion remains 
controversial due to discrepancies among different experiment approaches 
[46,56,62-65]. Nevertheless, most studies suggest that H1.4 has the strongest affinity 
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among all subtypes; H1.3 can be classified as of intermediate affinity, whereas 
histones H1.1 and H1.2 bind chromatin with low affinity. 
The linker histone heterogeneity is conserved among species, suggesting that 
the individual variants may have unique properties and functions [66]. In addition, H1 
variants have differential subnuclear distribution, indicating their specific roles in 
nucleus [56]. For example, over-expression of GFP-tagged proteins suggests that 
euchromatin is commonly enriched in histone subtypes H1.0, H1.1, H1.2 and H1.3, 
whereas H1.4 and H1.5 frequently accumulate within the heterochromatin region.  
 
1.1.3.2. Role of histone H1 in gene expression 
Several studies indicate that linker histone H1 subtypes interact with other 
transcription factors and agglomerate into large complexes that regulate the 
expression levels of specific target genes. For instance, histone H1.1 was shown to 
specifically interact with Barrier-to-autointegration factor (BAF), giving BAF access to 
chromatin and facilitating the higher order chromatin structure [67]. Also, histone 
H1.4 was found to play an important role in heterochromatization processes that 
leads to gene silencing through the recruitment of Polycomb complexes and 
heterochromatin protein 1 (HP1) [29,30,32].  
Interestingly, histone H1.5 was found to selectively interact with Ω promoter 
element controlling the expression of histone H3.2. The greatly elevated binding 
affinity was not observed on closely related H3.3 Ω promoter element, which 
indicates H1.5 high specificity towards H3.2 regulation [68]. Histone H1.5 also 
participates in expression regulation of myogenic determination factor (MyoD), by 
interacting with Msx1 (key regulatory element of MyoD). This cooperation leads to 
MyoD gene repression and inhibition of muscle differentiation [69]. On the other 







1.1.3.3  Manipulations of H1 subtypes in cell lines and animal models 
Although previous in vitro studies indicated histone H1 as a general repressor for 
gene expression, depletion of H1s in vivo suggests more specific effects of H1 in 
different organisms. RNAi silencing of H1.1 in nematode Caenorhabditis elegans 
causes the loss of gene silencing in the germline cells and blockade of germline 
development. Silencing H1 in Arabidopsis leads to pleiotropic developmental 
abnormalities and alterations in the DNA methylation patterns [71].  Although mice 
lacking one or two H1 variants have a normal total H1 levels and no apparent 
phenotypes, suggesting compensation among H1 variants [72], mice with knock-out 
of H1.2, H1.3 and H1.4, die by mid-gestation with a broad spectrum of defects and 
the remaining subtypes were unable to fully compensate for the loss of three H1 
subtypes [73].  This result establishes that H1 is essential for mammalian 
development. 
Mice with testis specific H1t deletion do not exhibit any phenotype or any defects 
in spermatogenesis [74]. Lack of histone H1t does not lead to its replacement by 
H1.1 or H1.2 during spermatogenesis, suggesting great diversity between somatic 
and testis-specific subtypes [75]. Oocytes microinjection with antisense 
oligonucleotides against H1oo reveals an essential role of this subtype in germinal 
oocytes maturation [76]. 
Knockdown or over-expression of individual H1 subtypes in cell culture shows 
that different H1 subtypes have specific effects on cell growth probably by either 
activating or repressing expression of specific genes. For example, in breast 
epithelial cell line studies, depletion of histone H1.2 leads to G1 arrest and an 
increase in apoptotic events [77]. In contrast, the over-expression of H1.2 in 3T3 
cells had no obvious effect on cell cycle but causes increased expression of some 
genes, such as c-myc and cyclophilin [78,79].  Knockout of histone H1.0 did not 
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produce any obvious phenotype in mouse model [80], but proper terminal 
differentiation in dendritic cells was not possible without H1.0 [81]. In comparison, 
over-expressed H1.0 in 3T3 cells significantly delayed the cell cycle progression by 
arresting in G1 and S phase and inhibited the expression of a number of genes 
responsible for cell cycle control.  
 
1.1.3.4. The effect of histone H1 on tumor growth and metastatic progress of  
               cancer cells 
For decades, researchers interested in linker histone H1 and its influence on 
cancer progression have been trying to comprehend its cytotoxic effect on tumor 
growth. It was found that histone H1 significantly inhibited growth of cancer cell 
lines, suggesting an anti-proliferating effect against leukemia and breast cancers 
[82,83]. Gine et al. showed that H1.2 is responsible for apoptosis induction in 
chronic lymphocytic leukemia, especially in patients with abnormal p53 functions 
[84].  The cytotoxic effect of H1 has been attributed to its structural homology with 
proteins secreted by activated macrophages and tufstin, a tetrapeptide stimulating 
macrophages migration, and their phagocytic and tumoricidal activity [85,86]. Since 
cationic amino acid sequence of linker histone acts like natural antibiotic peptide, it 
interacts with anionic phospholipid to disrupt negatively charged membranes leading 
to apoptosis [87].  
These experiments show that the scientists tried different approaches to verify 
histone H1 as a target gene or potential therapeutic agent. Although it is evident that 
linker histone variants have unique properties and play specific roles in eukaryotic 
cells, the literature still lacks the fundamental answers regarding the molecular 






1.2. Ovarian cancer 
 
1.2.1. Introduction and etiology 
Ovarian cancer is the ninth most common and the fifth most deadly cancer in 
women with a predicted 22,240 new diagnosed patients and 14,030 deaths in the 
United States in 2013 [88]. It is estimated that 1 in 81 American women will develop 
this type of cancer by the age of 85. According to these statistics, ovarian cancer was 
identified as the gynecological malignancy with the highest case-to-fatality ratio [89].  
The ovary is a paired female reproductive organ with main function to generate a 
fertilizable oocyte and to secrete steroid hormones responsible for preparation of the 
reproductive tract for fertilization. Single layer of surface epithelial cells covers the 
external surface of the ovary, and dense stromal tissue constitutes the internal 
scaffold. Other specialized cells essential for ovary functions include: germ cells 
(oocytes), granulosa cells, theca cells, and hilus cells (specialized in hormone 
production) (reviewed in [90,91]). 
 More than 90% of malignant ovarian tumors are believed to arise from the 
ovarian surface epithelium (OSE), a specialized coelomic mesothelial layer of cells 
covering and protecting the ovary.  The other malignancies derive from germ cells or 
supporting cells [92-94].   
The ovarian surface epithelium undergoes repetitive disruption and repair during 
the ovulation cycles, and is constantly stimulated to proliferate during the repair 
processes. Most ovarian cancers develop from the surface epithelium or 
postovulatory inclusion cysts situated in the ovarian stroma [95-98]. When trapped 
within inclusion cysts, epithelial cells are exposed to a unique microenvironment in 
which mutation accumulation may occur more favorably [96,97,99].  In fact, the 
“incessant ovulation” theory states that the cyclic disruption and repair of OSE may 
lead to accumulation of mutations in genes essential for cellular survival, leading to 
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ovarian cancer [100,101]. Contributing factors to increased risk of malignancy of 
ovarian epithelium may also include the stimulatory effect of Follicle-stimulating 
hormone (FSH), Luteinizing hormone (LH) and androgens on growth and cell 
division, as well as inflammation occurring during ovarian surface epithelium damage 
[102-105].    
A number of studies indicate that OSE cells can undergo epithelial-mesenchymal 
transition (EMT) in response to regenerative stimuli which may increase cell motility, 
proliferation and extracellular matrix modifications [106], and may acquire high 
metastatic potential after malignant transformation.  
Although ovarian cancer incidents are not associated with one particular cause 
and occur sporadically in population, there are several well-defined factors that 
increase the risk of developing ovarian carcinomas. For instance, women at older 
age and first or second degree relatives with the disease and women with infertility or 
endometriosis have an increased risk of developing this type of cancer  [107-109]. 
Also women carrying the mutations in breast cancer susceptibility gene 1 and 2 
(BRCA1 and BRCA2) are at higher risk to develop both ovarian and breast cancer 
often at an earlier age than the general population [110,111]. These mutations are 
found in 5-13% of all ovarian cancer cases [69,112]. Another factor that significantly 
increases the risk of developing ovarian carcinoma is a family history of hereditary 
nonpolyposis colorectal cancer (HNPCC, known as Lynch syndrome) associated with 
mutations in the DNA mismatch repair genes hMSH1, hMSH2, hPMS1 and hPMS2, 
or hereditary breast-ovarian cancer syndrome (HBOC) in which BRCA1 and BRCA2 
genes are involved [113,114]. Both syndromes increase ovarian cancer risk to 
around 50%. In addition, extensive pharmacological studies suggest that 
consumption of certain drugs increases the risk of ovarian cancer incidence in 
women. The list includes: hormone replacement therapy (especially received for 
more than 10 years) and long-term use of fertility drugs, such as clomiphene citrate 
or gonadotropins [115-120].    
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Early stages of ovarian cancer are usually asymptomatic or characterized by non-
specific symptoms until the disease reaches more advanced stages. Due to 
difficulties in correlating these subtle signs with developing ovarian cancer, patients 
are rarely diagnosed and treated at early stages, such as stage I/II [121].  Typical 
symptoms include: pelvic and abdominal pain, bloating, urinary disorders, vaginal 
bleeding, appetite loss, and back pain, all of which could have been over-looked as 
symptoms of menstrual irregularities, menopause, or other non-serious conditions. 
The accumulation of ascites in the abdominal cavity increases patients’ discomfort 
and intensifies pain in late stages [122].  
Ovarian cancer can be detected by physical and pelvic examination, transvaginal 
ultrasound, computed tomography scan (CT), biopsis and biomarker tests. 
Unfortunately, none of these techniques is reliable enough for detection of the early 
stages of ovarian cancer. In order to improve assay sensitivity and specificity, several 
biomarkers are simultaneously analyzed [123,124]. Recently developed multiplex 
assay combining six serum markers: leptin, prolactin, osteopontin, insulin-like growth 
factor II (IGF2), macrophage inhibitory factor (MIF) and CA-125, is thought to 
increase the test sensitivity to 95.3% and specificity to 99.4% [125].  
Histological grading (Grade 0 to 3) describes the malignancy of the tumor and 
indicates the probability of the cancer cells to metastasize to other tissues. Grade 0 
indicates non-invasive, borderline, or low malignancy potential tumors, Grade 1 
describes well-differentiated, low-grade tumors, with the cell morphology similar to 
normal cells, (good prognosis), Grade 2 depicts moderately differentiated tumors, 
and Grade 3 - poorly differentiated tumors with abnormal cell morphology (bad 
prognosis).  
In 1973 the World Health Organization (WHO) published the Classification of 
Ovarian Tumors providing a standardized reference tool reflecting the variation of the 
disease. The document was updated  in 1999 and approved by the International 
Society of Gynecological Pathologists (reviewed in [91,126,127]). Stage of the 
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ovarian surface epithelial tumors can be evaluated according to the TNM system 
established by the American Joint Committee on Cancer or the International 
Federation of Gynecology and Obstetrics system (FIGO). 
 
1.2.2. Prognosis and treatment   
Inefficient screening methods and detection of tumors in late stages correlate 
with poor recovery prognoses for ovarian cancer patients. 61% women already 
experience the advanced stages (III-IV) of cancer at the time of diagnosis and their 
five-year survival rate decreases drastically to 26.9% [128]. At these stages, cancer 
cells shed into the abdominal cavity fluids and metastasize to peritoneal organs as 
well as to lymph nodes and distant organs. Additional complications include: 
accumulation of ascites in the abdominal cavity, intestinal obstruction, loss of function 
of various organs.   
The most common treatment in ovarian malignancies is a combination of surgical 
intervention and chemotherapy. Current surgical strategy for advanced stages is 
cytoreduction, which often involves resection of tumors, reproductive organs, and 
sigmoid colon [129]. Additionally, women with stage III/IV cancer receive 
chemotherapy with platin (Cisplatin, apoptosis inducer) or taxane (Paclitaxel, mitotic 
inhibitor) through intraperitoneal (i.p.) or intravenous (i.v.) injection [130]. Studies in 
which those two administration techniques were compared, suggested that IP 
cisplatin and IP paclitaxel result in a longer disease progression-free survival and 
overall survival [130-132]. A combination chemotherapy regimen improved the 
median survival of patients with advanced ovarian cancer from 5-10% to 20-25% 
[133]. Despite this improvement, the majority of patients with ovarian malignancies 






1.2.3. Prevention and epidemiology 
Ovarian cancer occurs sporadically in the population with no known effective 
prevention practice. The disease is more prevalent in developed countries that in 
third world countries and mostly affects women between 55 and 74 years old. Less 
that 1% of epithelial ovarian cancers are detected in women younger than 30 years 
old and those malignancies are most probably germ cell tumors [134,135].    
Nevertheless, several studies suggested factors that may have protective effects 
and may reduce the risk of ovarian cancer.  For instance, oral hormonal 
contraception received for more than 10 years, was found to decrease the lifetime 
risk of developing ovarian cancer from 1.8% to 0.6% [136-138]. Multiple pregnancies 
and breastfeeding seem to have similar protective effect on women’s health [139-
141]. Lastly, some surgical procedures, such as tubal ligation and hysterectomy, 
were associated with reduced risk of ovarian cancer incidences even in patients 
carrying BRCA1 mutation [142].  
 
1.2.4. Molecular mechanisms of ovarian cancer progression 
Many studies indicate that steroid hormones play an important role in ovarian 
cancer etiology and progression. Hormonal shift from estrogens to androgens after 
menopause resulting in high androgen serum levels is believed to elevate the risk of 
ovarian cancer. Androgen receptor (AR) is expressed in OSE and is also found in 
95% of ovarian cancer cells suggesting its importance in ovarian cancer progression 
[143,144]. Several studies indicated that androgens treatment induces cellular 
proliferation and decreases cell death [145,146]. These physiological changes may 
be the results of repressing effect of androgens on TGFβ receptors (TβR-I and TβR-
II) expression, abrogating the normal growth inhibition signaling induced by TGFβ 
[147].   
Before ovarian cancer cells metastasize from the primary tumor, they need to 
undergo an epithelial-to-mesenchymal (EMT) transition resulting in decreased 
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attachment to basement membrane and adhesion between other cells [148]. This 
transition correlates with Mullerian differentiation during which the shape of the cells 
is altered and accumulation of E-cadherin, junctional complexes, and mucins 
(including MUC16 – CA125) are observed [149-151].  One of the most important 
molecules responsible for epithelial cell adhesion is E-cadherin. This membrane 
glycoprotein located at cell adherens junctions anchors epithelial cells to each other 
[152,153]. Downregulation of E-cadherin in cancer cells is caused by up-regulation 
and transcriptional repression by Sip1/ZEB2, Snail and Slug [154].  Shedding and 
survival of the cancer cells in detached form is also enhanced by upregulation of 
collagen-binding integrins and matrix metalloproteinase MMP-9 [155,156]. As a 
result, ovarian cancer cells can passively spread to peritoneum and omentum, 
carried by physiological movement of peritoneal fluids [157].  
Accumulation of ascites is a very common symptom of advanced stage of ovarian 
cancer. Ascites formation occurs when cancer cells obstruct subperitoneal lymphatic 
channels and prevent physiologically produced fluid from absorption. Additionally, 
secretion of vascular endothelial growth factor (VEGF) by cancer cells increases 
vascular permeability and promotes ascites production [158,159]. VEGF is an 
angiogenic protein remarkably upregulated in majority of ovarian cancer cells and its 
expression positively correlates with the degree of tumor malignancy [160,161]. A 
long list of VEGF inducers include: Hypoxia-Inducing Factor (HIF), Interleukins (IL-
1β, IL-6), Induction Growth Factor (IGF-1), Transformation Growth Factor (TGF-α, 
TGF-β), Basic Fibroblast Growth Factor (bFGF), and others [162-164]. Once the 
ovarian cancer tumor reaches a certain size, the diffusion can no longer provide a 
sufficient amount of nutrients required for its growth. In this case, VEGF stimulates 
vascular and lymphatic endothelium to form new blood vessels [165].  High 
expression of VEGF in tumors and its presence in serum and ascites indicates 
cancer progression and poor prognosis [166,167]. It was recently found that 
neovascularization process regulated by VEGF in ovarian carcinoma models can be 
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inhibited by specific anti-VEGF monoclonal antibodies and once this treatment is 
combined with Taxol therapy, significant improvement in tumors and ascites 
regression is observed [168].  
Oncogene disregulation and tumor suppressor inactivation are commonly found 
in ovarian cancer cells, which facilitate tumor progression at different stages.  Among 
the activated oncogenes, HER family of tyrosine kinase receptors draws particular 
attention of researchers. One of the family members, HER-2, is over-expressed in 
15% ovarian cancer tumors and associated with a poor prognosis [169,170]. Also, 
the PI3 kinase signaling pathway components, such as PI3, AKT, PTEN, are 
amplified, over-expressed or activated in more than 70% of ovarian cancers [171-
173]. As it is found in other malignancies, TP53 gene is also mutated in more than 
50% of ovarian carcinomas, especially in high-grade tumors [174-176].  
 
1.2.5. Epigenetics in ovarian cancer 
The epigenetic alterations have been observed in early and late stage ovarian 
cancers. Epigenetic changes, such as DNA methylation, histone modifications, and 
micro-RNA disregulation, have been noted in ovarian cancers and are subjected to 
intense investigations in recent years [177-180].  
In mammals, DNA methylation occurs predominantly in cytosines located at the 
side of guanines, frequently called CpG site (CpG dinucleotides) [181]. DNA 
methylation patterns are tissue and cell type-specific and disruption of DNA 
methylation may lead to tumor development [182]. Hypermethylation of gene 
promoters typically leads to gene silencing, and reduction of methyl groups in CpGs 
may increase transcription [183]. Tumor suppressor genes frequently reported as 
hypermethylated in ovarian cancer, such as BRCA1, hMLH1, hMLH2, ICAM-1, 
GATA4, estrogen receptor, p16 and SURVIVIN [184-190], whereas DNA 
hypomethylation was found in SERPINB5, Claudin4, HoxA10 [191-193].  
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Posttranslational histone modifications are also important mechanisms of 
epigenetic gene regulation. Acetylation, deacetylation, methylation, demethylation, 
phosphorylation, ubiquitination, ADP-ribosylation and sumoylation alter the 
biochemical properties of histones [194-198]. In general, loss of histone acetylation is 
associated with more compact chromatin conformation and decreased transcriptional 
activity. Histone acetylation is controlled by histone acetyltransferases (HATs), which 
add acetyl groups to specific lysine residues, and histone deacetylases (HDACs), 
which catalyze their removal. HDACs are frequently over-expressed in ovarian 
cancer tissues and play a significant role in ovarian carcinogenesis [70].  
Similarly, the accumulation of H3K9 trimethylation leads to chromatin compaction 
and gene silencing [199,200].  Interestingly, histone H3/lysine K4 methylation is 
associated with active genes which bring increasing complexity of histone code 
[201,202].    
microRNAs, small non-protein-coding RNA molecules, were recently introduced 
as epigenetic components of posttranscriptional gene downregulation [203]. They 
effectively inhibit the translation of their target genes by binding to their 3’ UTR region 
and creating the RNA-induced silencing complex (RISC) with Argonaute proteins and 
Dicer [204]. MicroRNA regulation is also altered in ovarian cancer tumors. For 
instance, miR-200a, miR-141, miR-200c and miR-200b are found over-expressed, 
but miR-199a, miR-140, miR-145 and miR-125b1 are downregulated [205]. 
microRNAs play key roles in both normal and pathologic ovarian activities by 
targeting the expression of specific genes.  
 Although the impact of aberrant epigenetic regulations on ovarian cancers is 







1.2.6. Potential histone H1 targets in ovarian cancer 
As mentioned above, linker histone H1 was previously analyzed in the context of 
breast cancer cell lines. Various subtypes were found to inhibit cell growth, induce 
apoptotic events, and even stimulate cytotoxicity in cancer cells. However, to date 
not much attention was paid to the putative linker histone H1 effects on ovarian 
cancer progression. 
Previous studies indicate that linker histone H1 subtypes specifically modulate 
the expression of target genes in direct or indirect manners in various contexts 
([40,206] ,unpublished observation). Here we demonstrate that individual H1 variants 
have distinct expression patterns in malignant ovarian adenocarcinomas compared 
with benign adenomas.  Through modulating H1 variants levels in ovarian cancer cell 
line, we have identified H19 as a direct target of H1.3 in OVCAR-3 cells.  H19 is non-
protein coding gene and an ovarian cancer biomarker. H19 is a well-known oncofetal 
gene frequently over-expressed in ovarian cancer as well as in other solid tumors. Its 
expression is regulated by epigenetic mechanisms, and recent studies showed that 
the level of linker histone H1 influence the amount of H19 in mouse embryonic stem 
cells [73,207].  Our studies here establish a mechanism by which a specific H1 
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H1 linker histones play a key role in facilitating higher order chromatin folding.  
Emerging evidence suggests that H1 and its multiple variants are important 
epigenetic factors in modulating chromatin function and gene expression.  Ovarian 
cancer is a devastating disease, ranking the fifth leading cause of all women cancer 
death due to its poor prognosis and difficulty in early diagnosis. Although epigenetic 
alterations in ovarian cancers are being appreciated in general, the role of H1 has not 
been explored.  Here, using quantitative RT-PCR assays, we systematically 
examined the expression of 7 H1 genes in 33 human epithelial ovarian tumors.  
Whereas the expression of H1.3 was markedly increased, the expression of H1.0, 
H1.1, H1.4 and H1x were significantly reduced in malignant adenocarcinomas 
compared with benign adenomas.  Strikingly, ovarian adenocarcinomas and 
adenomas exhibited characteristic expression patterns, and expression profiling of 7 
H1 genes in tumor samples discriminated adenocarcinomas vs. adenomas with high 
accuracy. These findings indicate that the expression of H1 variants is exquisitely 
regulated and may serve as potential epigenetic biomarkers for ovarian cancer.  
 
2.2. Introduction 
Ovarian cancer has the highest mortality rate among gynecological malignancies 
and ranks as the fourth most common cancer in women. Each year more than 
21,000 women are diagnosed with ovarian cancers and about 15,000 women die of 
the disease [208,209]. Due to the lack of effective screening methods and 
asymptomatic nature of ovarian cancers at early stages and during relapse, most 
women have advanced stage ovarian cancers at the time of diagnosis and the 5-year 
survival rate is only 25-50%. The etiology of ovarian cancers involves both genetic 
and epigenetic alterations.  Unlike genetic mutations, epigenetic changes, such as 
alterations in DNA methylation and histone modifications, are reversible, thus offering 
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an attractive avenue for therapeutic interventions. Better understanding of epigenetic 
changes associated with ovarian neoplasia will facilitate designing new strategies for 
early detection and effective therapy of ovarian cancers.   
Aberrant epigenetic regulations contribute significantly to ovarian cancer 
development and progression [177,210]. Accumulating evidence shows that 
alterations in DNA methylation and/or core histone modifications are responsible for 
silencing of tumor suppressor genes or upregulation of cancer-promoting genes in 
ovarian cancers [177,211,212].  Ovarian tumors also display genome-wide DNA 
hypomethylation and differential expression patterns of genes encoding histone 
modifying activities [210,213]. Such global changes in DNA methylation and histone 
modifications suggest that ovarian cancer cells adopt drastically different chromatin 
structure, because both DNA methylation and core histone post-translational 
modifications can profoundly impact on chromatin folding.  However, the role of linker 
histones, the key factors in mediating higher order chromatin structure has not been 
explored in ovarian cancer.  Here we take the first step to investigate a potential 
connection between specific linker histone variants with ovarian cancer through 
expression profiling of various H1 subtypes.   
Linker histone H1 binds to the nucleosome core particle, the basic repeating unit 
of chromatin consisting of an octamer of two molecules of each of the four core 
histones (H2A, H2B, H3 and H4) wrapped by 146 bp of DNA, and the linker DNA 
between nucleosomes to mediate higher order chromatin folding into a 30-nm fiber 
[10,214]. Consistent with its role in chromatin condensation and limiting genome 
accessibility, H1 acts as a general transcription repressor, repressing transcription by 
all three types of RNA polymerases in in vitro studies (reviewed in [214,215]).  
However, recent work using in vivo systems demonstrated a rather selective role of 
H1 in gene regulation, such that H1 can either activate or repress specific gene 
transcription under various physiological contexts [22,23,73,216-222].  
22 
 
The H1 histone family is the most divergent and heterogeneous group of histones 
among the highly conserved histone protein families.  All metazoan H1s share the 
same tripartite domain structure with a central globular domain flanked by N-terminal 
and C-terminal tail regions.  The globular domain is evolutionally conserved from 
yeast to humans.  Different H1 subtypes exhibit significant sequence divergence from 
one another, yet H1 subtypes are highly conserved during evolution in mammals, 
suggesting distinct functions for these subtypes.  There are 11 H1 subtypes (H1.0, 
H1.1, H1.2, H1.3, H1.4, H1.5, H1oo, H1t, H1x, H1t2 and H1LS1) identified in 
mammals that are differentially regulated during development and cellular 
differentiation [25]. H1.1 through H1.5 are somatic H1s that are ubiquitously 
expressed in all cell types and tissues. The synthesis of these 5 somatic H1s is cell-
cycle dependent and tightly regulated during development, such that each tissue has 
a characteristic composition of somatic H1 subtypes [36,223].  Although individual 
somatic H1 subtypes appear to be dispensable for normal mouse development, loss 
of three somatic H1 subtypes (H1.2, H1.3 and H1.4) by sequential gene targeting 
leads to embryonic lethality at mid-gestation, demonstrating that linker histones are 
required for mammalian development [72,224-228]. H1x is a more distantly related 
H1 variant whose RNA messages are present in many somatic tissues [43,229].  H1x 
proteins are found to accumulate in nucleoli in G1 phase and at chromosome 
periphery during mitosis in cultured cells, but its total protein level remains 
unchanged throughout cell cycle [230,231]. H1x is highly expressed in 
neuroendocrine cells and its expression is increased in neuroendocrine tumors [232].  
The replacement H1 variant, H1.0, is expressed mainly in differentiated and non-
dividing cells [233].  H1oo and H1t are oocyte- and testis- specific variants, 
respectively [42,234].  H1T2 and H1LS1 are two distantly related H1t-like proteins 
that are specifically expressed in spermatids [41,235].  Different H1 subtypes exhibit 
distinct in vivo binding dynamics in oocytes and during embryonic stem (ES) cell 
nuclear transfer [236]. These properties of H1 subtypes suggest that exquisite 
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regulation of high order chromatin compaction in various cellular processes may be 
achieved with different complements of H1 subtypes. 
In this study, we analyzed the expression pattern of H1 subtypes as a means to 
probe the specific chromatin status associated with malignant ovarian cancer.  The 
vast majority of malignant ovarian tumors are epithelial ovarian adenocarcinomas, 
which are derived from the ovarian surface epithelium [96].  While also derived from 
ovarian surface epithelium, ovarian adenomas are generally benign and do not have 
aggressive growth, nor do they metastasize to adjacent tissues. Here, we first 
systematically screened 14 malignant ovarian adenocarcinomas and 11 benign 
ovarian adenomas of the mRNA levels of all somatic and replacement H1 subtypes 
by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assays.  
We found that several H1 subtypes displayed drastically different expression patterns 
in malignant ovarian cancers compared with benign adenomas.  Furthermore, 
profiling and hierarchical clustering analysis of the expression levels of H1 subtypes 
can accurately discriminate between benign adenomas and malignant 
adenocarcinomas of all 25 samples, and correctly segregate ovarian adenomas from 
adenocarcinomas in a second set (blind test) of 8 tumor samples with 87.5% 
accuracy, suggesting a potential use of specific H1 subtypes as ovarian cancer 
biomarkers. 
 
2.3. Materials and methods 
2.3.1. Tumor samples 
A total of 33 tumor samples with an initial set of 25 tumors and a second set of 8 
tumors, including 18 benign serous cystadenomas and 17 malignant 
adenocarcinomas (Stages III and IV), were obtained from the Ovarian Cancer 
Institute (Atlanta, USA).  Primary tumor tissues were collected from patients who 
underwent surgery for removal of ovarian tumors at Northside Hospital (Atlanta, 
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USA) according to procedures approved by the Institutional Review Boards of 
Georgia Institute of Technology and Northside Hospital.  Patients had not been 
pretreated with chemotherapy at the time of surgery and the tumor tissues were snap 
frozen in liquid nitrogen immediately at the time of surgical removal.  
 
2.3.2. RNA isolation 
Tissue samples (75-100 mg) were ground with a PowerGen 125 homogenizer 
(Fisher Scientific) on ice in the presence of Trizol (Invitrogen, Carlsbad, CA) for 3 
times with 15 seconds each time to obtain crude homogenates. RNAs were 
subsequently extracted from the crude homogenates with Trizol according to the 
manufacturer’s instructions.  RNA samples were subsequently cleaned and 
concentrated using RNeasy Mini kit (Qiagen, Valencia, CA). The concentration and 
quality of RNA were measured and verified with a Nanodrop ND1000 
Spectrophotometer (Nanodrop, Wilmington, DE) and gel electrophoresis.  
 
2.3.3. Real-time quantitative RT-PCR (qRT-PCR) 
2.5 μg of total RNAs extracted from ovarian tumors were reverse transcribed into 
cDNAs using Superscript III kit (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s manual.  Since most histone RNAs do not have long poly-A tails, 
random hexamers (instead of oligo-dT) were used as primers in the reverse 
transcription reactions.  cDNAs were subsequently analyzed by real-time PCR 
analysis to quantitatively measure the expression levels of H1 subtype genes and 
house-keeping genes, e.g. glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
gene, which served as normalization controls.  Real-time quantitative PCR analysis 
with an RNA template was performed as RT(-) reactions to control for potential 
genomic DNA contamination.  In all of the reactions, the amount of PCR product 
produced from RT(-) reactions was less than 1% of that from RT(+) samples, 
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indicating that genomic DNA contamination, if any, was minimal.   Primers used for 
the real-time quantitative PCR analysis of H1 genes are listed in Table 2.1.  
The amount of cDNAs or DNA fragments was quantified and analyzed by real-
time PCR using iQ SYBR green PCR Supermix kit (Bio-Rad Laboratories, Hercules, 
CA) in a MyIQ Single Color real-time PCR Detection System (Bio-Rad).  Each primer 
pair was tested by a standard curve method using serial dilutions of DNA template 
and the dissociation curve was measured to assure that only the expected PCR 
product was produced.  All samples were typically analyzed in duplicate in at least 3 
independent runs.  Real-time data were recorded and quantified using iQ5 software 
provided by the manufacturer and expression values of H1 genes were normalized 
against that of GAPDH.  The genes for somatic H1s (H1.1-H1.5), H1.0, and H1x do 
not have introns. In order to cross-compare the relative mRNA message abundance 
within a tumor sample, the mRNA amount was  normalized by the primer coefficiency 
determined by qPCR using genomic DNA as template by standard curve method.  
The following program was applied for the experiment: 950C for 3 min., 950C for 10 
sec., 600C for 20 sec., 720C for 30 sec., 950C for 1 min. in 40 cycles.  
 
2.3.4. Statistical analysis 
Statistical analysis and p values of the differences between the median of H1 
expression levels in ovarian adenomas and adenocarcinomas were calculated by 
Mann-Whitney unpaired two-tailed test.  A p value of less than 0.05 was considered 
to be statistically significant. 
 
2.3.5. Immunoblotting 
Tumor samples were homogenized with a PowerGen125 homogenizer (Fisher 
Scientific) in Lysis buffer (30 mM Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% Na-
deoxycholate, 0.1% NP-40, Proteinase Inhibitor tablet). Protein concentrations of the 
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cell lysates were determined by Bradford Protein Assay (Bio-Rad). 20 μg of cell 
lysates were boiled for 5 minutes in Loading Buffer (2% SDS, 10% Glycerol, 50 mM 
Tris pH 7.0, 100 mM DTT, 0.1% bromophenol blue) before subject to 12% SDS-
PAGE. Proteins were subsequently transferred to a nitrocellulose membrane (Bio-
Rad) and blotted with a monoclonal antibody against H1.0 (Santa Cruz, sc-56695) 
[237], or GAPDH (Ambion, AM4300) as a loading control, followed by a Fluor® 680 
goat anti-mouse IgG secondary antibody (Invitrogen A21058).  The protein bands 
were visualized and quantified using the Odyssey Infrared Imaging System (LI-COR 
Biosciences).  
 
2.3.6. Cluster analysis 
Hierarchical clustering analysis was performed using the cluster 3.0 software 
from open source clustering software (http://bonsai.hgc.jp/~mdehoon/software 
/cluster/software.htm#ctv) and visualized using Treeview, which was developed 
based on program Cluster/Treeview [238].  
 
2.4. Results 
2.4.1. Analysis of the expression patterns of histone H1 subtypes using qRT-PCR 
We developed a set of real-time RT-PCR assays to quantitatively measure the 
mRNA levels of individual H1 variants.  Because mRNAs of most H1 genes contain a 
stem-loop structure at their 3’ untranslated regions (UTR) and lack the long poly-A 
























F' - CTCCTCTAAGGAGCGTGGTG - 5' 





F' - ACACCGAAGAAAGCGAAGAA - 5' 





F' - GGAGACTGCTCCACTTGCTC - 5' 





F' - GTCGGGTTCCTTCAAACTCA - 5' 





F' -GTCAAAAAGGTGGCGAAGAG - 5' 





F' - CTCGCAGATCAAGTTGTCCA - 5' 





F' - GTGGTTCGACCAGCAGAATG - 5' 






F' -GAGTCAACGGATTTGGTCGT - 5' 






F' - CTCTTCCAGCCTTCCTTCCT - 5' 
R' - AGCACTGTGTTGGCGTACAG - 5' 
116 57oC 
 
RNAs using random-primer based reverse transcription. By this means, we analyzed 
mRNA expression of all H1 subtypes, except those of the four germ cell specific H1s.  
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The H1 genes measured include the 5 somatic H1s (H1.1-H1.5), H1.0 and H1x.  
Table 2.1 lists RT-PCR primers utilized in these assays. 
 
2.4.2. Differential expression of the histone H1 subtype genes in ovarian   
            tumors 
To test if any of the H1 genes are differentially expressed during ovarian 
carcinogenesis, we measured the mRNA levels of 7 H1 genes in 11 benign ovarian 
adenomas and 15 malignant ovarian adenocarcinomas of stage III/IV using qRT-
PCR assays.  The mRNA levels of GAPDH and beta-actin remained constant across 
all tumor samples, indicating little variations in sample preparation and qRT-PCR 
analysis.  Each sample was analyzed in at least three independent experiments and 
the expression levels of H1 subtypes were normalized by the expression level of 
GAPDH.  Since all 7 H1s measured here are intronless, we normalized the relative 
primer efficiency for individual H1 subtypes by performing PCR reactions using the 
genomic DNA templates.  After adjusting for the relative efficiency of individual PCR 
reactions, we quantified relative mRNA expression levels of individual H1 subtypes 
(Figure 2.1) as well as the total H1 mRNA levels (Figure 2.2).  
Among the 7 H1 genes, H1.1, H1.4, H1.0, and H1x mRNA levels were 
significantly reduced in ovarian malignant adenocarcinomas compared with benign 
adenomas.  The reduction in expression values was highly statistically significant, 
with P values less than 0.0001 for H1.0, and equal to 0.006, 0.014, 0.003 for H1.1, 
H1.4 and H1x, respectively.  In contrast, H1.3 was increased 2.5-fold in malignant 
tumors (p=0.0029) (Figure 2.1).  The average expression levels of H1.2 and H1.5 did 
not appear to be statistically different between adenomas and adenocarcinomas (p 
>0.05).  Quantitation of total mRNA levels from all 7 H1 subtypes showed that, on 
average, the sum of total H1 mRNAs declined 40% in adenocarcinomas (p=0.0007) 




Figure 2.1. qRT-PCR analysis of mRNA levels of linker histone variants in ovarian tumors.  
Normalized mRNA expression levels of H1 subtypes are presented individually (A) and as a 
group (B). Y axis represents relative expression units. Each dot represents average 
expression values obtained from three independent measurements from one tumor sample. 
Data were normalized with the expression level of GAPDH and primer efficiency factor.         












































































































































































































































































































































Figure 2.2. Quantification of mRNA levels of total H1s and total somatic H1s.  A: Total 
relative expression units for all H1s. B: Total relative expression units for all somatic H1s 
(H1.1-H1.5).  Y axis represents relative expression units. Each dot represents the average 
value of the relative expression units obtained from three independent measurements of one 
tumor sample. Data were normalized with expression of GAPDH and primer efficiency factor.  
*: p<0.05; **: p<0.01; ***: p<0.001. 
 
This decrease in total H1 mRNA messages is mainly due to the reduction of H1.0 
mRNA levels because the total levels for S-phase dependent, stem-loop ended 
somatic H1 mRNAs (H1.1-H1.5 mRNAs) were similar between these two tumor types 
(Figure 2.2B), and the mRNA levels of H1x were negligible compared with other H1 
subtype mRNAs (Figure 2.1).  H1.0 mRNA, however, is polyadenylated, produced 
throughout cell cycle and processed differently than somatic H1 (H1.1-H1.5) mRNAs 
[223,239,240]. Interestingly, although ovarian adenomas and adenocarcinomas have 
similar levels of total S-phase dependent somatic H1 mRNAs (H1.1-H1.5) (Figure 
2.2B), the relative proportions of mRNAs expressed from different somatic H1 genes 
are drastically different (Figure 2.1).  This result suggests that individual somatic H1 
subtypes are transcriptionally differentially regulated in benign adenomas vs. 
malignant adenocarcinomas. 
We next determined if the drastic differences in H1.0 mRNA levels in adenomas 
vs. adenocarcinomas resulted in changes in H1.0 protein levels in these two types of 
tumors. We analyzed H1.0 protein levels in two adenocarcinomas (c647 and c756) 
and two adenomas (a564, a670), which contained H1.0 mRNA levels 3-fold of that 
A
Total H1s# Total Somatic H1s@
P<0.0001 P=0.5866
#: Total H1s include H10, H1x and all somatic H1s (H1.1-H1.5). @: Total somatic H1s include H1.1, H1.2, H1.3, H1.4 and H1.5.
B













from c647 and c756 (Figure 2.3A).  The two adenomas had significantly higher levels 
of H1.0 proteins than the two adenocarcinomas (Figure 2.3B), and quantitation of the 
protein band signals showed a 4-fold increase of H1.0 protein in the two adenomas. 
 
Figure 2.3. Reduced H1.0 expression in ovarian adenocarcinomas. A: qRT-PCR analysis of 
H1.0 mRNA messages. Y axis: relative expression units of H1.0. Expression values were 
normalized by the expression level of GAPDH.  B: Western blot analysis of H1.0 protein 
levels. GAPDH served as a loading control.   
 
Immunostaining of the sections of these 4 tumors indicated that H1.0 proteins 
were ubiquitously present in all cells, and that the two adenomas displayed stronger 
signals for H1.0 than adenocarcinomas (data not shown).  These results suggest that 
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2.4.3. Expression patterns of histone H1 subtypes discriminate ovarian  
            adenomas from adenocarcinomas  
Expression profiling of H1 subtypes demonstrated that multiple H1 genes exhibit 
differential expression levels in adenocarcinomas compared with adenomas (Figure 
2.1), suggesting characteristic H1 expression signatures associated with 
carcinogenesis. 
 
Figure 2.4. Hierarchical clustering diagram of differential expression data of 7 H1 subtypes in 
ovarian adenomas and adenocarcinomas. Red, green or black colors represent higher, lower, 
or no change in relative expression compared with the median expression level across all 
tumor samples, respectively. The dendrograms at the top and on the left show the clusters 
defined by similarities in expression patterns across the samples and genes. All 
adenocarcinoma samples cluster separately from adenomas. 
 
To determine whether H1 variant genes can serve as transcriptional classifier 





















































































































performed hierarchical clustering analysis of expression patterns of the H1 genes for 
these 25 ovarian tumors.   
Figure 2.4 shows that the clustering algorithm segregated all 25 samples into 
adenomas and adenocarcinomas accurately based on the similarities of H1 subtype 
expression patterns in these samples.  Expression patterns of H1 genes of all 11 
adenomas were more closely related to each other, forming a group separately from 
that of adenocarcinomas, which also clustered in a group.  
 
 
Figure 2.5. Validation of discriminating expression patterns of H1 subtypes in ovarian 
adenomas and adenocarcinomas.  Hierarchical clustering diagrams of expression profile of all 
7 H1 genes (A), or leaving out H1.0 (B), of all 33 samples were shown. Samples include 8 
blind test samples (marked with *) and 25 tumors from the initial batch. Both (A) and (B) show 
correct segregation of all but one (c821L) samples into ovarian adenomas vs. 
adenocarcinomas.  
 
To further test if analysis of mRNA expression patterns of H1 genes can predict 
ovarian adenomas vs. adenocarcinomas using these 25 tumor samples as 
templates, we obtained 8 additional tumor samples as a blind test set.  We analyzed 
H1 expression levels by qRT-PCR, and performed hierarchical clustering analysis of 
these 8 samples together with the initial set of 25 samples. We clustered each blind 
test sample together with the 25 samples, and such analyses correctly clustered all 
but 1 (c821L) blind test samples into their corresponding tumor groups, representing 
an accuracy of 87.5% (7 out of 8) in discriminating adenomas vs. adenocarcinomas 
within this blind test set.  Figure 2.5A shows a clustering diagram of all of the 33 

































































































































































































































































































































segregation of these two types of tumors. These results suggest that expression 
profiles of H1 variants can potentially serve as biomarkers to differentiate ovarian 
adenocarcinomas from adenomas.  To identify the minimum number of H1 genes 
whose expression levels contribute to accurate prediction of clustering of tumor 
types, we re-clustered all of the 33 samples using expression patterns from any 
combinations of 6 H1 genes (leaving out one H1 gene at a time).  Interestingly, as 
with clustering using all 7 H1 genes, leaving out H1.0 did not affect the correct 
discrimination of all samples but c821L (Figure 2.5B), whereas leaving out any of the 
5 somatic H1s and H1x  resulted in disruption of correct segregation of two or more 
tumor samples (data not shown).  
 
2.5. Discussion 
Numerous gene expression microarray analyses show that malignant tumors exhibit 
distinct expression fingerprints compared to normal tissues or benign tumors 
[74,241,242].  Changes in global and/or local chromatin structure contribute to the 
acquisition or maintenance of malignancy.  Indeed, increased nuclear staining and 
nuclear size are often early cytological abnormalities found with dysplasia [243].  The 
presence of multiple H1 histone variants provides an additional level of regulation in 
modulating chromatin folding, so it is likely that malignant transformation is associated 
with changes in the expression of various H1 subtypes.  However, expression changes 
in mRNAs of histone genes are often missed from microarray profiling studies.  This is 
because histone mRNAs, including that of most H1 genes, contain a stem-loop structure 
at their 3’ untranslated region (UTR) and lack a long poly-A tail, and are thus not selected 
when oligo-dT based reverse transcription assays are adopted.   
In the present study, we designed a set of qRT-PCR assays, coupling random primer 
based reverse transcription with real-time PCR, to quantitatively measure the expression 
of all H1 genes that are expressed in ovarian tumors.  Using this set of assays, we 
initially analyzed a total of 25 ovarian tumors (11 adenomas and 14 adenocarcinomas), 
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and found that benign ovarian adenomas and malignant adenocarcinomas have distinct 
expression patterns of several H1 genes.  Specifically H1.0, H1.1, H1.4 and H1x are 
significantly reduced in expression, whereas H1.3 has drastically increased expression in 
ovarian adenocarcinomas compared with adenomas.  Furthermore, clustering analysis 
of gene expression of these 7 H1 genes or 6 H1 genes (leaving out H1.0) segregates 
adenomas from adenocarcinomas with an overall accuracy of 97% for all 33 tumor 
samples (including 25 tumors of the initial batch and 8 samples of the blind test batch).  
These results suggest that H1 subtype genes display discriminative expression 
signatures which may serve as biomarkers and classifier genes to differentiate ovarian 
adenomas from adenocarcinomas.  These highly sensitive and quantitative real-time RT-
PCR assays can be attractive alternative or auxiliary diagnostic tools to current 
pathological analysis.  This possibility can be further investigated using a larger set of 
ovarian tumor samples.  With a larger set of ovarian tumor samples, it will also be 
possible to examine if subgroups from clustering analysis correlate with tumor 
progression stages and/or patient prognosis.   
Synthesis of somatic H1 subtypes (H1.1-H1.5) is primarily S-phase dependent, and 
the expression of H1 genes can be regulated at transcriptional level, post-transcriptional 
mRNA processing and stability, as well as protein degradation [223].  Cell cycle arrest or 
terminal differentiation in cell culture causes a reduction in H1.1, H1.3, H1.5 mRNAs and 
a slight decrease of H1.2 and H1.4 mRNAs [223], thus, we surmise that an increased 
proliferation rate in malignant tumors may lead to a reduction of the total levels of 
somatic H1 mRNAs in these cells.  Interestingly, careful quantification shows no 
difference in the combined levels of somatic H1 mRNAs (Figure 2.2B), instead, a change 
in the proportions of mRNAs from individual somatic H1 subtypes was observed in 
malignant adenocarcinomas compared with benign adenomas (Figure 2.1).  Although 
the relative proportions of protein levels for individual H1s do not recapitulate their 
relative proportions of mRNA levels due to different mRNA processing efficiencies [244] 
and varied turn-over rate of H1 subtypes [36,223,245], for a specific H1 subtype, the 
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increase or decrease in mRNA levels often leads to a corresponding change in its 
protein level [36,223], as is the case for H1.0 shown in this study (Figure 2.3).  We have 
previously observed similar fold increases in the levels of mRNAs and proteins of H1.0 
and H1.5, in H1.2/H1.3/H1.4 triple null mouse ES cells and embryos ([73], and Zhang 
and Fan, unpublished observation).  These studies suggest that changes in H1 subtype 
protein levels are likely to occur during ovarian tumor progression, and the trend of 
changes will probably follow the changes in the mRNA levels for a given H1 subtype.  
Individual somatic H1 subtypes have different DNA binding affinities and varying degrees 
of chromatin compacting ability [56,62,64,65], and they can be grouped into the strong 
condensers (H1.4 and H1.5), the intermediate condenser (H1.3) and the weak 
condensers (H1.1 and H1.2) in compacting minichromosomes [46]. Thus, changes in the 
protein levels of individual somatic H1s are likely to cause alterations in chromatin folding 
and compaction, modulating chromatin accessibility and function.   
It is noteworthy that clustering analysis using the expression levels of only 5 somatic 
H1 genes can  segregate 23 of the initial 25 tumor samples correctly (92% accuracy) into 
adenomas vs. adenocarcinomas (data not shown), suggesting that the distinctive 
expression patterns of the somatic H1s (H1.1-H1.5) alone can discriminate ovarian 
adenocarcinomas from adenomas with high confidence.  It will be interesting to 
investigate how these changes in the expression of specific H1 subtypes are brought 
about in malignant ovarian adenocarcinomas.  Interestingly, leaving out H1.2 and H1.5, 
whose expression levels do not differ significantly in the two types to tumors, leads to 
incorrect segregation of more tumor samples by unsupervised clustering analysis (data 
not shown), significantly dampening the discriminative power of H1 profiling in classifying 
adenomas vs. adenocarcinomas. We postulate that there may be cross-regulation 
among the somatic H1 subtypes, and the mRNA levels of H1.2 and H1.5 are probably 
connected to the expression levels of the other H1 subtypes.  
H1.0 mRNAs and proteins are significantly reduced in adenocarcinomas (Figure 2.1, 
Figure 2.3). H1.0 is considered to be a differentiation specific H1, as it accumulates in 
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terminally differentiated and non-dividing cells (reviewed in [233]). H1.0 expression is low 
or undetectable in rapidly dividing cells or tissues, but is induced or upregulated during 
differentiation and senescence [36,81,233,246].  The significantly lower expression of 
H1.0 in ovarian adenocarcinomas is consistent with the higher proliferation rate of 
ovarian malignant adenocarcinomas compared with ovarian benign adenomas. As the 
smallest subtype with the highest percentage of positively charged amino acids among 
the H1 family proteins, H1.0 has high affinity for DNA and can strongly compact 
minichromosomes in vitro [46,247].  Thus, accumulation of H1.0 proteins would be 
consistent with an increased level of chromatin compaction and heterochromatin found 
in terminally differentiated cells [248]. The reduction of H1.0 expression in ovarian 
adenocarcinomas observed in this study may indicate a reduced level of chromatin 
compaction in these malignant tumor cells.    
Besides the potential of serving as biomarkers for discriminating ovarian 
adenocarcinomas vs. adenomas, the distinctive expression patterns of histone H1 
subtypes may contribute to the causes for carcinogenesis of ovarian cancer.  Alterations 
of H1 levels and chromatin compaction impact on a variety of cellular properties.  
Modulating levels of specific H1 subtypes can lead to changes in cell cycle and 
proliferation rate in a cell type specific and H1 subtype dependent manner [77,79].  
Depletion of H1.2 in human breast cancer cell line T47D by inducible shRNA causes cell 
cycle arrest at G1-phase, although knockdown of other somatic H1 variants in T47D 
does not show similar effects on cell cycle [77].  Interestingly, over-expression of H1.0, 
but not H1.2, in mouse 3T3 cells, leads to a transient delay in S-phase entry [79] .  
Although deletion of three somatic H1s, H1.2, H1.3 and H1.4, does not appear to affect 
cell growth rate in mouse ES cells [73], deletion of all 6 H1 genes in chicken B 
lymphocyte cell line DT40 significantly impairs cell growth and causes elongation of all 
stages of the cell cycle [249].  Reduced expression of strong condensers, such as H1.0 
and H1.4, combined with a marked increase of intermediate condenser (H1.3), may 
result in a more open and accessible chromatin conformation in ovarian 
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adenocarcinomas. This is likely to cause expression changes of specific genes, which 
may contribute to carcinogenesis.  On the other hand, it has been shown that degrees of 
global chromatin condensation per se impact on DNA damage response, cell migration 
and invasiveness [250-252]. Global chromatin de-condensation, either by depletion of 
H1.2/H1.3/H1.4 in mouse ES cells or induced by treatment with histone deacetylase 
inhibitors (HDACi) in human breast cancer cell line MCF7, results in increased DNA 
damage response [250]. Migration signals cause an increase in heterochromatin, and 
induction of chromatin de-condensation by HDACi in mouse melanoma cell line B16-F1 
inhibits cell migration [252].  Taken together, these studies indicate that the effects of H1 
subtypes as well as the role of overall H1 levels and general chromatin condensation on 
cancer cell properties are multifaceted and context dependent.  Our findings that 
distinctive expression patterns of H1 subtypes discriminate ovarian adenomas from 
adenocarcinomas extend the roles of H1 variants into ovarian cancer, and suggest that a 
further investigation of the functional roles of specific H1 subtypes in ovarian cancer cells 
is warranted. 
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CHAPTER 3:  Histone H1.3 suppresses H19 oncogene expression and  
   cell growth of OVCAR-3 ovarian cancer cells. 
 
3.1. Abstract 
Ovarian cancer is a deadly gynecological malignancy for which novel biomarkers and 
therapeutic targets are imperative for improving survival. Previous studies have 
suggested the expression pattern of linker histone variants as potential biomarkers 
for ovarian cancer.  To investigate the role of histone H1 in ovarian cancer cells, we 
over-expressed one of the major somatic H1 variants, H1.3 in epithelial ovarian 
cancer cell line, OVCAR-3. We find that over-expression of H1.3 decreases the 
growth rate and colony formation of OVCAR-3 cells.  We identify histone H1.3 as a 
specific repressor for non-coding oncogene H19.  Over-expressing H1.3 suppresses 
H19 expression, whereas H1.3 knockdown increases its expression.  Furthermore, 
we demonstrate that histone H1.3 over-expression leads to increased occupancy of 
H1.3 at the H19 regulator region encompassing the imprinting control region (ICR) 
concomitant with increased DNA methylation and reduced occupancy of insulator 
protein CTCF at the ICR.  Moreover, we show that elevated expression of H19 
increases proliferation, whereas its depletion suppresses growth rate of OVCAR-3 
cells. Finally, we demonstrate that over-expression of H1.3 combined with H19 
knockdown synergistically decreases growth rate of ovarian cancer cells.  
 
3.2. Introduction 
Ovarian cancer has the highest mortality rate among gynecological malignancies, 
and is currently the fourth most common cancer in women. Each year, more than 
22,000 women are diagnosed with ovarian cancer and about 15,000 women die of 
the disease, primarily due to difficulty in detecting its presence in earlier, often-
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asymptomatic stages [121,253]. The survival rate of women who suffer from ovarian 
cancer can be improved if diagnostic tests of high specificity and accuracy are 
clinically available. In order to reach this goal, new therapeutic targets and novel 
biomarkers need to be characterized on a molecular basis.  
The etiology of ovarian cancers involves both genetic and epigenetic alterations. 
The genetic components of malignant transformations are not well understood, 
although mutations in BRCA1, TP53, RB1, PTEN and other genes are sporadically 
found in ovarian cancer cases (reviewed in [176]).  Epigenetic aberrations, such as 
DNA methylation, histone modifications, nucleosome positioning and post-
transcriptional gene regulation by microRNAs, are well established in the 
development and progression of ovarian cancer (reviewed in [177,254]).  
Organization of chromatin, DNA stabilization, and facilitation of nucleosome 
folding are the major structural functions of H1 linker histones [255]. H1 linker 
histones interact with linker DNA at the dyad axis of the nucleosome at the entry and 
exit sites of the nucleosomal DNA and participate in multiple cellular processes 
occurring on the chromatin template, such as gene expression, DNA replication and 
repair [13,14,16,256].  
In mammals, there are 11 H1 variants.  Five major somatic H1 subtypes: H1.1 – 
H1.5 variously are expressed in both dividing and non-dividing cells. Also a somatic 
H1.0 mainly accumulates in differentiated cells. Tissue specific H1s include testis-
specific H1t, H1T2, and HILS1, as well as the oocyte-specific H1oo. The recently 
identified H1x is present in very low amount and found to have higher expression in 
neuroendocrine cells [41,42,229,232,257]. Their heterogeneity is conserved among 
species and suggests that the individual subtypes may have unique properties and 
functions in the cell [66].  
Besides mediating higher order chromatin folding, linker histone H1 has been 
shown to regulate gene expression in vivo in a specific manner.  However, it is not 
clear whether those genes are directly regulated by a specific H1 variant.  Here, we 
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report the identification of an important non-coding oncogene H19 as a direct target 
specifically regulated by H1.3 in epithelial ovarian cancer cells.   
Aberrant expression of H19 occurs in ovarian cancer and other types of cancers 
[258-260].  H19 is often over-expressed in ovarian cancer, and has been suggested 
as a biomarker for ovarian cancer [261]. H19 is an oncofetal gene located on human 
chromosome 11 and is highly expressed in fetal tissues but suppressed in most 
tissues after birth [262,263]. H19 belongs to an imprinted gene family controlled by 
the imprinting control region (ICR) important for mammalian development [264,265]. 
Expressed from the maternal allele, H19 encodes for a spliced, capped and 
polyadenylated non-coding RNA highly conserved in evolution [266]. It is also a 
precursor for a microRNA, miR-675, which targets genes essential for growth, 
development and carcinogenesis, such as RB and Igf1r [267-269]. The H19 locus 
was recently found to produce an antisense transcript, called H19 opposite tumor 
suppressor (HOTS) and a long intergenic transcript, 91H, which indicates the great 
complexity of this region [270,271]. H19 gene regulation has been shown to be 
regulated by chromatin structure and epigenetic mechanisms, including DNA 
methylation, CTCF isolator and enhancer activity (reviewed in [272,273]). 
In this study we investigate the role of linker histone H1 variants in regulating H19 
transcript in ovarian cancer. We utilize over-expression and shRNA knockdown 
approaches to modulate the expression levels of H1s and H19 mRNA in OVCAR-3 
cells. We find that linker histone H1, as a potent epigenetic regulator, directly 
represses the expression of H19 gene that leads to phenotypic changes in ovarian 
cancer cells. The results suggest a novel mechanism by which H1.3 regulates H19 







3.3. Materials and Methods  
3.3.1. Cell culture  
OVCAR-3 and 293T cells were cultured in RPMI-1640 (OVCAR-3) or DMEM 
(293T) media containing 10% and 20% fetal bovine serum, respectively, in a 
humidified incubator with 5% CO2 at 37
oC.  
3.3.2. Expression vectors construction and stable cell lines generation  
Genomic DNA (gDNA) of OVCAR-3 cells was extracted with Allprep DNA/RNA 
Mini kit (Qiagen) and used as template DNA for amplification of the human H1 variant 
gene coding sequences by PCR. PCR products containing H1 variant coding 
sequence were cloned into a modified pcDNA3 cloning vector at the  EcoRI/XhoI 
restriction sites, and sequence verified.  The backbone of the modified pcDNA3 
vector contained flag sequence (5’-GACTACAAAGACGATGACGACAAG-3’) at the 
N-terminal to the start codon. The primers designed for cloning PCR are listed in 
Table A.1. The expressional vector of H19 was purchased from Genescript.  The 
BamHI site was mutated into SacI, and the ApaI site was changed into BamHI using 
a site-directed mutagenesis kit according to the manufacturer’s manual (Clontech). 
The H19 gene flanked by SacI and BamHI was inserted into pcDNA3 vector and 
sequence verified.   
OVCAR-3 cells were transfected with pcDNA-H1s or pcDNA-H19 vectors by a 
Lipofectamine 2000 reagent according to the manufacturer’s recommendations. Two 
days post-transfection, the cells were treated with 400 μg/ml G418 (Geneticin, 
Invitrogen) for 4 to 5 weeks and resistant clones were picked up and cultured.    
3.3.3. Lentivirus production and inducible/stable cell lines generation  
pTRIPz (inducible) and pGIPz (stable) shRNA lentiviral systems (Thermo 
Scientific) were utilized to knockdown H19 and histone H1.3 expression. 293T cells 
were co-transfected with lentiviral target vectors containing shRNAmir or H1s mRNA 
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and the TransLenti Viral Packing System (Thermo Scientific) to obtain viral particles 
capable of infecting OVCAR-3 cells. Virus titration, transduction of target cell lines, 
and puromycin selection were performed according to the manufacturer’s protocol. 
The cells were sorted by Green Fluorescence Protein (GFP) or Red Fluorescence 
Protein (RFP) expression to enrich the populations with cells highly expressing 
shRNAmir or H1s mRNA respectively (BD FACS Aria III Cell Sorter, Beckman 
Coulter). Seven cell lines with integrated shRNA were generated: OV-3/scrambled-
shRNA, OV-3/shH19(tz), OV-3/shH1.3(tz), OV-3/fl.H1.3(H)/scrambled-shRNA, OV-
3/flH1.3(H)/shH19(tz), OV-3/flH1.3(H)/shH1.3(tz), OV-3/flH1.3(H)/shH1.3(gz). 
3.3.4. RNA isolation and RT-PCR  
RNAs were extracted with Trizol (Invitrogen) according to the manufacturer’s 
instructions.  RNA samples were further cleaned and concentrated using RNeasy 
Mini kit (Qiagen). The concentration and quality of RNAs were measured with 
Nanodrop (Nanodrop, Wilmington, DE) and verified by gel electrophoresis. 2.5 μg of 
total RNA were reverse transcribed into cDNA using Superscript III kit (Invitrogen) 
according to the manufacturer’s protocol. Random hexamers and oligo-dT were used 
as primers in the reverse transcription reactions in 1:1 ratio.  cDNAs were 
subsequently analyzed by real-time PCR analysis to quantitatively measure the 
expression levels of H1 histone subtypes, H19, and house-keeping genes, such as 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which served as  
normalization controls. The sequences of H19 primers were as follows: F: 5’-
ACCACTGCACTACCTGACTC-3’ and R: 5’-CCGCAGGGGGTGGCCATGAA-3’. H1 
subtypes and control primers used for the real-time quantitative PCR analysis were 
previously published [274]. The relative expression of selected genes were quantified 
and analyzed by real-time PCR using iQ SYBR Green PCR Supermix kit (Bio-Rad 
Laboratories, Hercules, CA) in a MyIQ Single Color real-time PCR Detection System 
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(Bio-Rad) as previously described [275]. All samples were typically analyzed in 
triplicates in at least 3 independent runs.  
3.3.5. microRNA extraction  
microRNAs were extracted from 5x106 cells with mirVana miRNA Isolation kit 
(Invitrogen) according to the manufacturer’s protocol. The quality of obtained 
microRNAs was confirmed by gel electrophoresis. Reverse transcription of 500 ng 
microRNAs was performed with miScript Reverse Transcription kit (Qiagen). Primers 
for miR-675 were as follows: F: 5’-GTTATTGGTGCGGAGAGGGCC-3’, universal R: 
5’- TGAATCGAGCACCAGTTACG-3’, and internal control primer U6: F: 5’- 
GCGCAAGGATGACACGC.  
3.3.6. Western blotting 
 The cells were lysed in Lysis buffer (30 mM Tris pH 8.0, 150 mM NaCl, 0.1% 
SDS, 0.5% Na-deoxycholate, 0.1% NP-40, Proteinase Inhibitor tablet) and total 
histones were extracted as previously described [275]. A Bradford Protein Assay 
(Bio-Rad) was performed to determine total protein concentration of each sample. 
Samples were boiled at 95ºC for 5 minutes with Loading Buffer (4% SDS, 20% 
Glycerol, 100 mM Tris pH 7.0, 200 mM DTT, Coomassie Blue dye). Samples were 
run in 12% SDS-PAGE gels and transferred to nitrocellulose members (Trans-blot 
Transfer Medium, Bio-Rad) for two hours. The membranes were blocked for one 
hour in 4% non-fat milk in PBS at room temperature, incubated over night at 4ºC with 
primary antibody against: flag-tagged proteins M2 (Sigma, Cat. F1804), H1.2 
(Abcam, Cat. ab4086), H1.3 (Abcam, Cat. ab24174), phospho-H1.4 (Sigma, Cat. 
H7664), H1.5 (Abcam, Cat. ab24175), H1.0 (Santa Cruz, Cat. sc-56695), H3 
(Abcam. Cat. ab1791), beta-actin (Sigma, Cat. A5441) and then with secondary 
antibodies: IRDye680 Goat anti-Rabbit (Li-COR, Cat. 926-32221), IRDye800 Goat 
anti-Rabbit (Rockland, Cat. 611-0132-122) or Goat anti-Mouse (Molecular Probes, 
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Cat. A21058) for one hour at room temperature in a 1:10000 ratio. Bands were 
visualized using Odyssey Infrared Imaging System (LI-COR Biosciences). 
3.3.7. Growth curves, MTT and clonogenic assays  
The growth rate assay of selected cell lines was performed by seeding 3x104 
cells per well in triplicates and counting them every 2 days with Multisizer Coulter 
Counter (Beckman Coulter). After 16 days, a growth curve was generated and 
compared with control cell lines. MTT assay was performed to evaluate the metabolic 
activity of the tested cells. The clones and control cell lines were seeded at the 
density of 1500 cells per well in 96-well plate. Triplicates of each cell line were tested 
every other day for 16 days. Two hours after incubation with MTT compound 
(yellow), mitochondrial succinate dehydrogenase in metabolically active cells formed 
insoluble formazan crystals (purple), which were resolubilized with stop solution (10% 
SDS, 0.1% HCl). The amount of formazan crystals produced by the cells was 
proportional to metabolic activity (of living cells), which was measured by 
spectrometer at 570 nm wavelength. For colony forming (clonogenic) assay, 0.1 ml, 
0.3 ml, and 1 ml of 103 cells per ml were seeded on 3.5-cm dishes in triplicates and 
were cultured in a humidified incubator with 5% CO2 for 4 weeks as previously 
described with modifications [276]. RPMI-1640 medium with 20% FBS was changed 
every 3 days. After incubation, the cells were rinsed with cold PBS and fixed with 
PBS:Methanol (1:1 ratio) for 2 minutes, then incubated in Methanol for 10 minutes, 
and dried. 3 ml 1% Crystal violet was added to each dish for 10 minutes. The 
colonies were rinsed with H2O and counted.  
3.3.8. Cell cycle analysis 
The cell cycle was determined after Propidium Iodide DNA staining followed by 
flow cytometry analysis. The cells were collected from an exponentially growing 
culture, washed with cold PBS and fixed in ice-cold ethanol. After 30 minutes of 
incubation at room temperature the cells were layered with bovine serum and 
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centrifuged for 5 minutes at 300xg to remove cellular debris. The cells were treated 
with RNase A (400 units/ml) for 30 minutes at 37° to eliminate the double-stranded 
RNA and stained with Propidium Iodide (50 μg/ml in 1.12% sodium citrate) for at 
least 30 minutes. The stained cells were detected by flow cytometer (BD FACSDiva, 
Beckman Coulter) and analyzed with FlowJo software. 
3.3.9. Microarray and data analysis 
Genome-wide expression profiles of OVCAR-3 and selected clones were 
compared to vector only transfected cell lines. Total RNAs were isolated with TRIzol 
reagent (Invitrogen), purified, labeled and used for microarray hybridization to human 
Affymetrix ST1.0 array at Einstein Genomic Facility.  Data were analyzed using 
Expression Console (Affymetrix). Selected gene changes were confirmed using qRT-
PCR. The results were normalized over the housekeeping gene GAPDH and 
compared with the controls. Cluster analysis was performed to group differentially 
expressed genes into subgroups according to their expression patterns (Cluster 1.0). 
A list of differentially expressed genes was further analyzed with Ingenuity IPA 
Software to determine the pathways or functional groups of genes involved.   
3.3.10. High Performance Liquid Chromatography 
Histone proteins were extracted using 0.2 N sulfuric acid as previously described 
[275]. 100 μg of total histone preparations were injected into a C18 reverse phase 
column (Vydac) on an AKTA UPC10 system (GE Healthcare). Fractions 
corresponding to the H1.2/H1.3/H1.4 peak from HPLC analysis were collected and 
subjected to mass spectrometry analysis on a Qstar XL MS/MS system (Applied 
Biosystems) with electrospray ionization (ESI) as the ionization method. Analyst QS 
software (Applied Biosystems) was used for data acquirement and analysis. Also, 




3.3.11. Chromatin Immunoprecipitation  
ChIP assays were performed as previously described [73] with modifications. The 
following antibodies were used: anti-flag (Sigma, Cat. F1804), anti-CTCF (Santa 
Cruz, Cat. Sc15914), anti-H3 (Abcam, Cat. 1791) and anti-IgG (Millipore, Cat. 12-
370). Briefly, cross-linked chromatin was sheared by sonication to DNA fragments 
ranged from 400 to 1,000 bp. Small portions of chromatin for each sample was 
aliquoted and stored for % Input.  20 μl of Dynabeads Protein G (Invitrogen) was 
incubated with 2 μg of antibody for 7 hours in 4°C. Dynabeads were washed three 
times with 1 ml PBS containing 0.5% BSA, then mixed with 50 μg of chromatin and 
left rotating overnight in 4°C. After incubation Dynabeads were washed five times 
with Washing Buffer (50 mM HEPES pH 7.6, 1 mM EDTA pH 8.0, 500 mM LiCl, 0.7% 
Sodium Deoxycholate, 1% NP-40) and once with PBS. Protein/DNA complexes were 
eluted in 100 μl Elution Buffer (50 mM Tris-Cl pH 8.0, 10 mM EDTA pH 8.0, 1% SDS) 
at 65°C for 20 minutes with agitation every 3 minutes, and incubated overnight at 
65°C. DNA was purified with Qiagen DNA Isolation column (Qiagen). Lastly, the 
concentration of immunoprecipitated DNA was measured using Qubit Fluorometer 
(Invitrogen). The amount of each specific DNA fragment in immuno-precipitates was 
determined by real-time PCR. PCR reactions were prepared with the iQ SYBR Green 
Supermix (Bio-Rad) and were analyzed in a MyIQ Real-Time PCR Detection System 
(Bio-Rad). All samples were typically analyzed in triplicate in three independent 
experiments. The primers used to analyze H19 regulatory region and control primers 
are listed in Table A.2. All results were normalized over the % Input. The values from 
ChIP with control antibody (IgG) were typically less than 5% of the ChIP values. 
3.3.12. Bisulfite treatment and DNA methylation analysis  
Genomic DNA was isolated from cells with Qiamp DNA kit (Qiagen). 1 μg of DNA 
was treated with the pGenome DNA Modification kit (Millipore) according to the 
manufacturer’s manual. Treated DNA was dissolved in 50 μl H2O, and 1 μl of treated 
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DNA was used in each PCR reaction as previously described [73]. The primers used 
to generate PCR products from the bisulfite-converted DNA are listed in Table A.3. 
The PCR products were subsequently cloned using the TOPO TA cloning kit 
(Invitrogen), and clones containing the converted DNA inserts were selected for 
sequencing. DNA sequences were analyzed with BiQ analyzer. 
 
3.4. Results  
3.4.1. Determination and analysis of individual H1 variants in OVCAR-3 cells 
OVCAR-3 cell line is a well-characterized epithelial ovarian cancer cell line 
frequently used to study molecular mechanisms of ovarian cancer malignancies. This 
cell line was derived from a patient with epithelial ovarian adenocarcinoma, which 
represents more than 90% of all ovarian cancer malignancies. We characterized the 
expression of individual histone H1 variants by combining HPLC, Mass Spectrometry 
and Western blotting methods (Figures 3.1 and 3.2).  
 
Figure  3.1: Expression of histone H1 subtypes in OVCAR-3 cell line. A: RP-HPLC of histone 
proteins. B: Mass spectrometry of fraction indicated with red arrow in (A).  
 
Total histones were isolated from OVCAR-3 cells by sulfuric acid extraction and 
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histone H1 variants separation according to their hydrophobic/hydrophilic properties 
(Figure 3.1A). Three fractions of putative H1 subtypes were collected, lyophilized and 
analyzed by Mass spectrometry.  
Figure 3.2: Characterization of peaks eluted from HPLC of histones extracted from OVCAR-
3/H1 clones. Histone extracts from stable clones with over-expressed H1 subtypes were 
analyzed by HPLC (left). Individual peaks were collected and analyzed by Coomassie and 
Western blotting using indicated antibodies. Red arrows indicate the fractions collected for 










































The fraction 3 was identified as a mixture of histones H1.2, H1.3 and H1.4 (Figure 
3.1B). Since histone H1.3 is ubiquitously expressed among different cell types and 
we found mRNA transcripts present at high levels in OVCAR-3 (data not shown), we 
expected that its protein levels would be comparable to the other subtypes. 
Surprisingly, its amount occurred to be much lower that H1.2 and H1.4 (Figure 3.1B). 
To verify the identity of individual peaks of the HPLC fractions, we generated the cell 
clones with over-expressed N-terminally flagged histone H1 subtypes. The total 
histones were extracted and analyzed by HPLC and the eluted fractions were 
collected and verified by Western blotting (Figure 3.2). These results demonstrate the 
peak identity and the relative amount of each linker histone variant in HPLC profile 
from OVCAR-3/H1 cell lines.  
 
3.4.2. Over-expression of histone H1.3 inhibits cell growth and colony  
             formation  
Histone H1.3 is a one of the major somatic H1 variants that is abundantly 
expressed in tissues as well as in both dividing and non-dividing cells, and play an 
important role in chromatin folding.  However, its specific role in gene regulation and 
cellular functions remain elusive and it has often been omitted in cancer related 
studies despite its abundance. Surprisingly, compared with other somatic H1 
variants, H1.3 protein level is particularly low in OVCAR-3 despite high levels of 
mRNA transcripts, suggesting that the endogeneous H1.3 is translationally inhibited 
in OVCAR-3 cells.  The low expression of endogeneous H1.3 in OVCAR-3 cells 
provides a good experimental system for us to investigate the role of H1.3 in ovarian 
cancer cells using an over-expression approach.   
Stable clones over-expressing FLAG-H1.3 were generated by transfecting 
pcDNA-H1.3 construct into OVCAR-3 cell line (Figure 3.3A). 48 clones resistant to 
G418 selection were selected and screened using an anti-FLAG antibody (Figure 
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3.3B). The clone with the highest FLAG-H1.3 levels (designated as OVCAR-
3/H1.3(H)) was used for further characterization.   
 
Figure 3.3: Generation of OVCAR-3/H1.3 clones. A: Vector containing N-terminally FLAG 
tagged H1.3 subtype. B: Western blotting of H1.3 over-expressed clones.  OVCAR-3 cells 
were transfected with a pcDNA-FLAGH1.3 construct, G418 resistant clones were picked and 
analyzed by Western blotting using an anti-FLAG antibody. Coomassie staining shows equal 
loading of cell lysates.  Lane 1: OVCAR-3; Lane 2: OVCAR-3 transfected with pcDNA3 vector 
(designated as OV-3/vector only); Lane 3-9: OVCAR-3/FLAGH1.3 clones. A clone (lane 3, 
marked with an asterisk) with the highest expression of FLAG-H1.3 was used for further 
investigation and A low expressing clone denoted with number sign was used in microarray 
analysis. 
 
 To determine the effects of over-expression of FLAGH1.3 on the expression 
of other H1 variants, HPLC and Western blotting were performed on OV-3/H1.3(H) 
clone as described above. The results indicated that FLAG-H1.3 co-eluded in the 
same fraction as the endogenous protein, proving that the biochemical properties of 
exogenous H1.3 does not differ from the endogeneous H1.3. The antibody against 













H1.3 detected a strong band of FLAG-H1.3 in fraction 3 of the OV-3/H1.3(H) sample, 
indicating that the amount of FLAGH1.3 is several fold higher compared with  the 
endogenous H1.3 (Figure 3.4A, D).  However, quantitation of H1 to nucleosome ratio 
from the HPLC profile indicates that the total H1 levels are comparable in OV-
3/H1.3(H) clones and OVCAR-3 cells (Figure 3.4B). The presence of FLAGH1.3 
protein (23.2 kDa) in fraction 3 eluted from HPLC was further confirmed using Mass 
Spectrometry (Figure 3B). Interestingly, the protein levels of H1.0, H1.2 and H1.4 
protein are all reduced to certain extent (Figure 3.4C,D, E) by calculation of individual 
H1 to nucleosome ratio from HPLC analysis (Figure 3.4C) and Western blotting using 
total histone extracts (Figure 3.4E).  This phenomenon is reminiscent of H1 
compensatory regulation that occurs during subtypes expression alterations by H1 




Figure 3.4. Over-expression of histone H1.3 modulates the amount of other linker histone 
subtypes in OV-3/H1.3(H). A: HPLC profile of linker histone H1 subtypes in OVCAR-3 and OV-
3/H1.3(H) cells. B: Mass spectrometry profiles of fraction 3 obtained from HPLC of OVCAR-3 and 
OV-3/H1.3(H) cells. C: Calculation of individual H1 subtype per nucleosome as well as total H1s 
per nucleosome in OV-3/H1.3(H) and OVCAR-3 based on HPLC results. H1 to nucleosome is 
determined by the ratio of A214 values of individual H1 subtype to that of half of the H2B peak. 
Results were obtained from 3 independent experiments. D: The presence of histone H1 subtypes 
in fractions 1, 2, and 3 determined by Western blotting. 4. FLAGH1.3 co-elutes in the same 
fraction 3 as the endogenous H1.3 protein. E: The comparison of individual H1 subtypes in OV-
3/H1.3(H) and OVCAR-3 by Western blotting. 
Anti: H1.2
OVCAR-3    OV-3/H1.3(H)
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To characterize the phenotypic changes by H1.3 over-expression, we compared 
the growth rate, metabolic activity, colony forming abilities and cell cycle profiles of 
OVCAR-3 and OV-3/H1.3(H). OV-3/H1.3(H) cells displayed reduced growth rate by 
growth curve and MTT assays (Figure 3.5). Cell cycle analysis indicated that OV-
3/H1.3(H) cells have a higher population of G1 than OVCAR-3 cells as well as a 
lower percent of S phase cells compared with OVCAR-3 cells (Figure 3.6). These 
results indicate that over-expression of H1.3 subtype reduces cell proliferation and 
affects the metabolic activity in OVCAR-3 (Figure 3.5A and 3.5B).  
 
Figure 3.5: Histone H1.3 over-expression alters the growth rate in OVCAR-3 cell line. 
Analysis of A) growth rate, B) metabolic activity (MTT) and C) expression levels of H1.3 of 




To exclude the possibility that the inhibitory effects on cell proliferation in OV-
3/H1.3(H) is due to clonal variation, OV-3/H1.3(H) cells were infected with a vector 
expressing shH1.3 to knockdown H1.3 levels in OV-3/H1.3(H) cells. H1.3 levels was 
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with OV-3/H1.3(H) cells (Figure 3.5C). The reduced growth rate in OV-3/H1.3(H) 
cells was alleviated in OV-3/H1.3(H)/shH1.3(GZ) cells (Figure 3.5A,B).  
 
 
Figure 3.6: Cell cycle analysis of OVCAR-3 and OV-3/H1.3(H) cells.  The cells were stained 
with Propidium Iodide and analyzed with flow cytometry. p values: * < 0.05, **<0.01.   
 
We next examined the clonogenic capacity of these cells and found that OV-
3/H1.3(H) clone formed between 10 to 15 times less colonies than OVCAR-3 cells, 
suggesting that increased levels of histone H1.3 impairs clonogenic abilities in 
OVCAR-3 cells (Figure 3.7).  This inhibitory effect is partially abolished by H1.3 
knockdown in OV-3/H1.3(H)/shH1.3(GZ) cells (Figure 3.7). 
 
Figure 3.7: Histone H1.3 over-expression inhibits colony formation. A: Representative results 
of colony formation assay. B: The quantitation of colonies formed 4 weeks post seeding (in 




























































3.4.3. Over-expression of H1.3 leads to specific changes in gene expression  
To identify genes and pathways affected by H1.3 subtype over-expression, we 
performed Affymetrix Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA) at 
Einstein Genomic Core Facility.  We compared the genome-wide transcriptomes of 
OV-3/H1.3(H), OV-3/H1.3(L), OVCAR-3/V.O. and OVCAR-3 cell lines (Figure 3.8A & 
B). Two biological repeats were performed for each cell line and data were 
normalized over that from OVCAR-3/V.O. cells. Genes showing consistent changes 
of 2-fold or more were selected for cluster analysis (Cluster 3.0) (Figure 3.8).  Among 
genes with significant expression changes, 76 were upregulated and 88 were 
downregulated genes in OV-3/H1.3(H) cells compared with OVCAR-3 cells. To 
confirm the results of microarray, several differently expressed genes were analyzed 
by RT-PCR (Figure 3.9), and all of them showed expression changes comparable to 










Figure 3.8: Comparison of global gene changes in OV/H1.3 and OVCAR-3 cells by 
microarray analysis. A: Genes with more than 2-fold expression difference were selected for 
analysis. The duplicates of OVCAR-3, OV-3/H1.3(H) and OV-3/H1.3(L) results were 
normalized over OV-3/V.O. and clustered by Cluster 1.0 software.  B: Cluster of gene 
changes divided on subgroups with different expression patterns with adjacent gene list. 
Genes altered only in OV-3/H1.3(H) are shown in group II and IV, genes altered in both 
clones – group I and V, and genes altered only in OV-3/H1.3(L) – group III.  
 
 
According to microarray, GJA1, RBP1 and Il12A genes were downregulated, 
whereas GDA, GHR and PTPRR genes had increased expression in OV-3/H1.3(H) 
in comparison to control cell lines. CTCF gene which expression did not alter in OV-
3/H1.3(H), served as negative control (data not shown). Similar expression results 
were obtained by RT-PCR analysis (Figure 3.9).  
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Figure 3.9: RT-PCR analysis of indicated genes in OVCAR-3 cells. Upper panels show 
representative genes downregulated in OV-3/H1.3(H), lower panels are three representative 
genes upregulated in OV-3/H1.3(H). Bar: SD. 
 
H19 was found to be one of the genes most dramatically disregulated in OV-
3/H1.3(H) cells. H19 expression was also significantly suppressed in OV-3/H1.3(L) 
clone which suggested that H19 gene is a target of linker histone H1.3. Analysis of 
the molecular pathways and cellular processes altered in OV-3/H1.3(H) cells using 
IPA software indicate that cell proliferation, cell adhesion, programmed cell death, 
cell migration and immune response were all affected. An representatitive IPA hit 



























































































































































Figure 3.10: A selected hit map with genes altered in OV-3/H1.3(H) clone. H19 marked as a 
gene of interest.  
 
 3.4.4. Oncogene H19 is a direct target of H1.3 in OVCAR-3 cells.  
The finding that H19 is down-regulated in OV-3/H1.3(H) cells combined with 
previous report that H19 is upregulated in H1.2/H1.3/H1.4 triple knockout mouse 
embryonic stem cells, prompted us to investigate if the regulation of H19 expression 
is specifically affected by H1.3 or other H1 subtypes.  To investigate this, we utilized 
the stable OVCAR-3/H1 cell lines over-expressing one of the six somatic H1 
subtypes (H1.0 - H1.5) as shown in Figure 3.2. The expression levels of exogenous 
FLAG-H1 were measured by Western blotting with an anti-FLAG antibody.  While all 
of the OV-3/H1 cell lines exhibit comparable signals of exogenous FLAG-H1 for each 
individual H1 variant (Figure 3.11), H19 transcript level was only dramatically 
suppressed in OV-3/H1.3(H) line as measured by RT-PCR (Figure 3.12), suggesting 




Figure 3.11: OV-3/H1 clones of each individual H1 variant express comparable levels of 
FLAG-H1 variants. 15 μg of total histone extracts were analyzed by Western blotting with an 
anti-FLAG antibody. Coomassie staining of core histones serves as loading control. OV-
3/V.O.: OVCAR-3 cells transfected with pcDNA vector without inserted H1 genes.  
 
 
Figure 3.12: Relative expression of the H19 mRNA transcript level in each stable clone 
measured by RT-PCR. H19 expresion was normalized over GAPDH. Bar: SD  
 
  
H19 is a precursor for miR-675 [267,268,277]. To determine if the repression of 
H1.3 on H19 expression also leads to reduction in miR-675 expression, we extracted 
low molecular weight enriched RNA from OVCAR-3, OV-3/V.O. and OV-3/H1.3(H) 
cells and analyzed miR-675 expression.  RT-PCR results indicated that the relative 
amount of miR-675 is drastically suppressed in OV-3/H1.3(H) when compared with 
control cell lines (Figure 3.13), suggesting that over-expression of histone H1.3 also 
causes down-regulation of miR-675.  Thus, in addition to H19, H1.3 may also control 

































Figure 3.13: miR-675 is downregulated in OV-3/H1.3(H) cells. microRNAs were extracted 
from cells and relative expression of miR-675 was measured by RT-PCR. Bar:SD.  
 
 To further test if the expression of H19 is directly dependent on the amount of 
histone H1.3 in cells, we generated OV-3/shH1.3(TZ) cell line in which the 
expression of endogenous H1.3 level in OVCAR-3 cells can be knocked down under 
the induction by doxycycline to induce the expression of shRNA against H1.3 in a 
pTRIPZ vector.    
 
Figure 3.14: H19 expression is elevated by endogenous H1.3 knockdown in OVCAR-3 cells. 
A: The expression level of H1.3 in OV-3/shH1.3(TZ) cells 10 days post 1 μg/ml Doxycycline 
treatment. B: Protein level of histone H1.3 in OV-3/shH1.3(TZ) 10 days after Dox treament. C:  
The effect of H1.3 knockdown on H19 expression in OV-3/shH1.3(TZ)+Dox (10 days). 
  
 
The efficiency of shH1.3 knockdown was determined using RT-PCR and Western 
blotting (Figure 3.14A & B). H1.3 knockdown by shRNA results in a 81% reduction of 
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knockdown led to a 50% elevation in H19 mRNA transcript.  Similarly, knockdown 
histone H1.3 level in OV-3/H1.3(H) cells using stable expression of shRNA against 
H1.3 (Figure 3.5C) led to an upregulation of  H19 transcript (Figure 3.15).  
 
 
Figure 3.15: H1.3 knockdown in OV-3/H1.3(H) cells abolishes the repression effects of H1.3 
on OVCAR-3 cells. H19 expression was measured by RT-PCR. Bar: SD.  
 
 
3.4.5. Epigenetic mechanisms of H19 repression mediated by H1.3         
Chromatin structure and epigenetic mechanisms play a key role in H19 
expression regulation [278]. Aforementioned findings suggest that, among somatic 
H1 variants, H1.3 is the specific variant that represses H19 expression in OVCAR-3 
cells. To investigate the potential mechanisms by which H1.3 regulates H19 
expression in OVCAR-3 cells, we first set out to determine the binding profiles of 
H1.3 across entire H19 gene locus, including 5.2 kb upstream regulatory region, by 
Chromatin Immunoprecipitation.    
Soluble chromatin from OV-3/H1.3(H), OV-3/H1.3(L) and OVCAR-3 cells were 
Immunoprecipitated using an anti-FLAG antibody (Sigma) and immunoprecipitated 
DNA was analyzed by quantitative real-time PCR to determine the enriched 































the entire H19 upstream regulatory region with 3-5-fold higher signals than that in 
OV-3/H1.3(L) cells (Figure 3.16).  These results indicate that H1.3 over-expression 
results in preferential accumulation of H1.3 at H19 regulatory regions. 
 Figure 3.16: H1.3 over-expression preferentially increases H1.3 occupancy at H19 
regulatory region. A: The occupancy of H1.3 was analyzed on distal and proximal promoter 
region. B: Control region - GAPDH promoter region, contains no H1.3. Bar: SD.  
 
H19 expression is controlled by the imprinting control region (ICR) located within 
the H19 upstream regulatory region. In humans, this region also contains 7 CTCF 
binding sites, of which methylation status dictates accessibility for the CTCF isolator 
[279,280]. Previous studies have shown that DNA methylation at ICR region 
represses the expression of H19 with higher DNA methylation leads to reduced 
expression of H19.  To determine if increased H1.3 binding at H19 ICR leads to 
changes in DNA methylation at H19 ICR, we picked two regions of highest increase 
in H1.3 binding (marked as region 1 (R1) and region 2 (R2)) as well as a region 
without dramatic H1.3 accumulation (R3) for analysis of DNA methylation by bisulfite 
sequencing.  
As determined previously using quantitative bisulfite restriction analysis (QUBRA) 
[281] and confirmed by bisulfite sequencing in our experiment, H19-ICR region is 

























methylation of CpG sites surrounding CTCF binding sites R1 and R2 in OV-3/H1.3(H) 
cells are significantly increased by 2.3- and 5.8-times, respectively, whereas H19 
proximal promoter (R3) remain hypermethylated in both OVCAR-3 and OV-3/H1.3(H) 
cells (Figure 3.17).  Analysis of DNA methylation status of the rescue cell line OV-
3/H1.3(H)/shH1.3 indicated a reduction of methylation in R1 and R2, but not in R3.  
These results indicate that increased occupancy of H1.3 at H19 distal promoter 
region leads to hypermethylation of the H19-ICR. 
Figure 3.17:  Increased H1.3 leads to higher DNA methylation at H19 regulatory regions. A: 
Methylation analysis was performed on CTCF (Region R1 and R2) and H19 proximal promoter 
region (Region R3). B: Calculations of percent methylation in analyzed regions and CTCF binding 
sites. ● CG methylated, ○ CG unmethylated. p values: **<0.01, ***<0.001.  
 
It was previously documented that the methylation of CTCF binding sites in H19-
ICR prevents CTCF binding [280]. CTCF ChIP results showed that CTCF occupancy 
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at H19-ICR is reduced in OV-3/H1.3(H) cells compared with that in OVCAR-3 (R1 
and R2) cells. The c-myc site containing well-established CTCF binding sites is 
included as a positive control site, the c-myc gene body site was analyzed as a 
negative control site (Figure 3.18). The reduced occupancy of CTCF protein on H19-
ICR in OV-3/H1.3(H) cells suggests that over-expression of histone H1.3 may 
prevent CTCF from binding to the H19 ICR region and regulating H19 expression in 
OVCAR-3 cells.  
Taken together, these findings indicate that linker histone H1.3 directly regulates 
H19 expression in ovarian cancer cells by binding to H19-ICR, increasing DNA 
methylation and preventing CTCF from binding to CTCF sites in H19 ICR.    
Figure 3.18: CTCF is partially depleted from H19-ICR in OV-3/H1.3(H).  
 
      
3.4.6. Over-expression of histone H1.3 and reduction of H19 synergistically  
            suppresses ovarian cancer cell growth  
Previously, it was demonstrated that the expression of H19 mRNA promotes 
proliferation and enhances tumorigenesis in cancer cells [282-285]. To determine if 
the inhibitory effect of H1.3 on OVCAR-3 growth rate is mediated through its 
regulation on H19 expression, we first investigated the effects of modulation of H19 
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Over-expressing H19 transcript in OVCAR-3 by transfecting the cells with a 
pcDNA-H19 vector (schematic diagram Figure 3.20A) increased H19 transcripts 20-
fold in comparison with untransfected cells. This upregulation resulted in significant 
increase in cell growth rate when compared with non-transfected OVCAR-3 cells 
(Figure 3.20A & B). OV-3/H1.3(H)/H19 cell line in which H19 is over-expressed in 
OV-3/H1.3(H) cells will be generated to test if increase in H19 transcript can “rescue” 
the growth inhibitory effects by H1.3 over-expression.  These experiments indicated 
that upregulation of H19 increases the growth rate of ovarian cancer cells. 
 Figure 3.19: Over-expression of H19 transcript in OVCAR-3 cells leads to increased growth 
rate. A: RT-PCR analysis of H19 expression. H19 expression was normalized over GAPDH. 
B: Growth curves of OV-3/H19 and OVCAR-3 cells. Medium was supplemented with 1 μg/ml 
Doxycycline throughout the whole experiment Bar: SD. 
 
In order to determine whether simultaneous over-expression of H1.3 and 
depletion of H19 would synergistically impair the growth of ovarian cancer cells, we 
established an OV-3/H1.3(H) cell line with knocked down H19 transcript by utilizing 
the commercially available pTRIPz lentiviral inducible system (schematic diagram 
Figure 3.20A). The induction effect by Dox can be visualized by RFP expression 
(Figure 3.20B). The generated stable cell line showed a 75% reduction in H19 
expression at eight days post-induction in OVCAR-3 cells (Figure 3.20C) and 92% 
reduction in OV3/H1.3(H) cells (Figure 3.21A). Growth curve analysis of OVCAR-
3/shH19 and OVCAR-3 cell lines indicated that depletion of H19 significantly reduced 
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growth rate in ovarian cancer cells after induction of shH19 by Doxycycline (Figure 
3.20D & 3.21B).   
 
Figure 3.20: Modulation of H19 transcript affects the growth rate of OVCAR-3 cells. A: 
Schematic diagram of pTRIPz-shH19 vector. B: Doxycycline induced RFP expression at Day 
2 and 8 in OV-3/shH19 cells. C: Efficiency of H19 knockdown induced by 16-day Doxycycline 
treatment measured using RT-PCR. D: Negative effect of H19 knockdown on OVCAR-3 
growth rate. Medium was supplemented with 1 μg/ml Doxycycline throughout the whole 
experiment. Bar: SD. 


































































Figure 3.21:  Synergistic effects of H1.3 over-expression and H19 depletion on OVCAR-3 
growth rate. A: The expression of H19 in OVCAR-3, OV-3/shH19, OV-3/H1.3(H), OV-
3/H1.3(H)/shH19. B: The growth curves of those cell lines. Medium was supplemented with 1 
ug/ml Doxcycline for the entire experiment duration. Bar: SD. 
  
 
These results suggest that over-expression of linker histone H1.3 and 
simultaneous depletion of H19 transcript synergistically suppress the growth rate in 




3.5. Discussion  
H19 is an oncofetal gene whose expression is frequently elevated in many solid 
tumors [258,259,261,286]. Its upregulation has been associated with increased 
proliferation, tumorigenesis, cell cycle progression and cell migration 
[282,283,287,288]. However, tumor suppressor activity of H19 has also been 
reported in several studies [289,290], and thus the role of H19 in carcinogenesis is 
still controversial.  
In this study, we uncovered a novel function of H1.3 in inhibiting ovarian cell 
growth, likely mediated through repression of H19 gene.  By utilizing over-expression 
and knockdown approaches, we generated cell lines with modulated expression of 







































histone H1 subtypes and H19 transcript. Systematic analysis of generated clones 
demonstrated that linker histone H1.3 is the only somatic H1 variant capable of 
effective suppression of H19.  Our results also suggest that this regulation is likely to 
be a direct effect. In addition, over-expression of histone H1.3 represses the growth 
rate and colony formation ability in OVCAR-3 cells suggesting its tumor suppressor 
properties. The synergistic effect of H1.3 over-expression and H19 depletion in 
ovarian cancer cells suggest a new strategy of combining H1.3 modulation with H19 
for therapeutic intervention.  
We have investigated the mechanism by which H19 is suppressed by H1.3 and 
found that H1.3 preferentially accumulates at H19 ICR, leading to increased DNA 
methylation and reduced binding of CTCF insulator binding protein at H19-ICR.  
These results suggest that H1.3 epigenetically represses H19 expression through 
DNA methylation as well as an antagonism between H1 and CTCF.  Although a link 
between H1 and DNA methylation at regulating specific genes have been revealed in 
several previous studies [73,291,292], our study is the first one suggesting a highly 
specific regulation of H19 expression by H1.3 in vivo.  However, this inhibitory effect 
appears to be regulated by H1.3 in a highly specific manner because other H1 
variants did not repress the expression of H19 with the comparable levels of FLAG-
H1 as to that of FLAG-H1.3.  The mechanism by which H19 specifically repressed by 
H1.3 through DNA methylation can not be fully accounted by the interaction between 
H1 variants and DNA methyltransferases (DNMTs) ([207], Cao, Ho, and Fan, 
unpublished observation), because multiple H1 variants are found to interact with 
DNMTs.  Other mechanisms may also contribute to the regulation of H19 by H1.3.  
For example, histone H1 was found to inhibit the remodeling activities of ySWI/SNF, 
hSWI/SNF, and xMi-2, whose functions are to move, destabilize, or restructure 
nucleosomes [293]. Thus, it is conceivable that histone H1.3 may act as a specific 
repressor of H19 gene by blocking the chromatin-remodeling complex to access H19 
regulatory region.  
70 
 
Additionally, linker histone H1 has been shown to interact with SirT1 and histone 
lysine methyltransferase Ezh2 ([30], [29] reviewed in [294]).  Histone H1 has been 
shown to be deacetylated at H1K26 by SirT1 and methylated by Ezh2.  Methylated 
H1 binds heterochromatin protein 1 (HP1), which could lead to transcription 
repression of the target region [32]. Therefore, the direct effect of H1.3 on H19 gene 
silencing in human ovarian cancer cells may be due to direct interaction between 
linker histone H1 and other chromatin proteins or factors. 
Histone H1 is increasingly being suggested to contribute to epigenetic regulation 
in cancer cells. Understanding the underlying molecular mechanisms may lead to 
new approaches to manipulate gene expression. In this study we generated stable 
cell lines with tagged H1 subtypes and we established inducible system in which 
protein levels of histone H1 variants can be readily modulated. Those cell lines will 













CHAPTER 4: Expression analysis of mammalian linker histone subtypes 
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Linker histone H1 binds to the nucleosome core particle and linker DNA, 
facilitating folding of chromatin into higher order structure.  H1 is essential for 
mammalian development [227] and regulates specific gene expression in vivo 
[10,23,206].  Among the highly conserved histone proteins, the family of H1 linker 
histones is the most heterogeneous group.  There are 11 H1 subtypes in mammals 
that are differentially regulated during development and in different cell types.  These 
H1 subtypes include 5 somatic H1s (H1a-e), the replacement H1.0, 4 germ cell 
specific H1 subtypes, and H1x [25].  The presence of multiple H1 subtypes that differ 
in DNA binding affinity and chromatin compaction ability [46,56,62,65] provides an 
additional level of modulation of chromatin function.   
 
 
Figure 4.1: Overall scheme of expression analysis of mammalian linker-histone subtypes. 
 
 
Thus, quantitative expression analysis of individual H1 subtypes, both of mRNA 
and proteins, is necessary for better understanding of the regulation of higher order 
chromatin structure and function.    
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Here we describe a set of assays designed for analyzing the expression levels of 
individual H1 subtypes (Figure 4.1).  mRNA expression of various H1 variant genes 
is measured by a set of highly sensitive and quantitative reverse transcription-PCR 
(qRT-PCR) assays, which are faster, more accurate and require much less samples 
compared with the alternative approach of Northern blot analysis. Unlike most other 
cellular mRNA messages, mRNAs for most histone genes, including the majority of 
H1 genes, lack a long poly-A tail, but contain a stem-loop structure at the 3’ 
untranslated region (UTR) [223].   Therefore, cDNAs are prepared from total RNA by 
reverse transcription using random primers instead of oligo-dT primers.   Real-time 
PCR assays with primers specific to each H1 subtypes (Table 4.1) are performed to 
obtain highly quantitative measurement of mRNA levels of individual H1 subtypes.  
Expression of housekeeping genes are analyzed as controls for normalization.    
The relative abundance of proteins of each H1 subtype and core histones is 
obtained through reverse phase high-performance liquid chromatography (RP-HPLC) 
analysis of total histones extracted from mammalian cells [225,226,295].  The HPLC 
method and elution conditions described here give optimum separations of mouse 
H1 subtypes.  By quantifying the HPLC profile, we calculate the relative proportion of 
individual H1 subtypes within H1 family, as well as determine the H1 to nucleosome 













4.2.1. Sample preparation and RNA extraction  
4.2.1.1)  Before RNA extraction, all working surfaces and pipettes should be wiped 
with 70% ethanol and treated with RNase decontamination solution, such as RNase 
Zap®. This practice reduces the chances of RNase contamination and RNA 
degradation. Wear gloves for all procedures. 
4.2.1.2)  To extract RNA from mouse tissue, dissect the organ of interest from 
euthanized mouse, and wash the tissue in ice cold Phosphate Buffered Saline (PBS: 
0.13 M NaCl, 5 mM Sodium phosphate dibasic heptahydrate, 5 mM Sodium 
dihydrogen phosphate heptahydrate, pH 7.4). Proceed immediately to RNA 
extraction in step 4.2.1.4. If fresh tissue is not to be processed for RNA extraction, 
the tissue samples should be snap frozen in liquid nitrogen immediately and be 
stored at -80oC for later use.   
4.2.1.3) If RNA is to be extracted from adherent cell culture, aspirate culture media, 
rinse with sufficient amount of PBS, and add Trizol Reagent (Invitrogen) onto the 
plate and proceed to step 4.2.1.4.  For cells grown in suspension, harvest the cells 
and pellet cells by centrifugation.  Discard media, rinse the pellets briefly with PBS, 
and pellet the cells with centrifugation.  Add Trizol Reagent and proceed to step 
4.2.1.4.  
4.2.1.4)  Sufficient Trizol Reagent is necessary for obtaining high quality RNA.  Use 1 
ml Trizol Reagent to extract RNA from 50 - 100 mg tissue, 5 - 10 x 106 cells (for 
suspension cultures) or per 3.5 cm plate (for adherent cultures).  Homogenize the 
tissue in Trizol Reagent with Polytron PT2100 homogenizer (or equivalent).  Proceed 
to extract RNA from tissue samples or cells according to the manufacturer’s manual 
for Trizol Reagent (Invitrogen). 
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4.2.1.5) RNA concentration is measured using Nanodrop 1000 (Thermo Scientific) 
and RNA quality is analyzed by gel electrophoresis.  The typical yield ranges from 1-
10 μg of RNA per mg of tissue or 5-15 μg of RNA per 1 x 106 cultured cells. To 
eliminate the potential contamination of RNA from trace amount of genomic DNA, 
RNA samples are treated with RNase-free DNase (Sigma AMP-D1) according to the 
manufacturer’s instruction. Repeat RNA concentration determination and gel 
electrophoresis to ensure no degradation of RNA from this treatment. Store extracted 
RNA at -80oC.   
*Note: RNA may also be extracted using RNAeasy kit (Qiagen) according to the kit 
manual, or by DNA/RNA kit (Qiagen) if both DNA and RNA are desired.  
 
4.2.2. Quantitative reverse transcription PCR (qRT-PCR)  
4.2.2.1)  Total RNA is reverse transcribed into cDNA using Superscript III First-strand 
Synthesis System (Invitrogen).  Since mRNA of most H1 genes lack poly-A tails, it is 
critical to use random hexamers instead of oligo-dT as primers for cDNA synthesis. 
However, if expression analysis of genes with polyadenylated messages at low levels 
is also desired, a mixture of random hexamers and oligo-dT should be used in the 
reverse transcription (RT) reaction to improve the reverse transcription efficiency of 
polyadenylated mRNAs.  
4.2.2.2) Perform the RT reaction according to the manufacturer's manual. Briefly, 
• In a 0.5 ml PCR tube, combine 5 μg of total RNA, 1 μl of 50 ng/μl random 
hexamers, 2 μl of 10 mM dNTP mix, and add DEPC-treated H2O to make the total 
reaction volume as 10 μl. Mix well and incubate for 5 minutes at 65ºC, followed by 1 
minute incubation on ice. 
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• Prepare 10 μl of cDNA Synthesis Mix: 2 μl of 10xRT buffer, 4 μl of 25 mM 
MgCl2, 2 μl of 0.1M DTT, 1 μl of RNaseOut (40U/μl), 1 μl of SuperScript III RT (200 
U/μl) and add it to RNA/primer mixture.  





Mouse histone nomenclature Human histone nomenclature 
Gene name Accession no. Gene name Accession no. 
Histone H1a Hist1h1a NM_030609 HIST1H1A (H1.1) NM_005325 
Histone H1b Hist1h1b NM_020034 HIST1H1B (H1.5) NM_005322 
Histone H1c Hist1h1c NM_015786 HIST1H1C (H1.2) NM_005319 
Histone H1d Hist1h1d NM_145713 HIST1H1D (H1.3) NM_005320 
Histone H1e Hist1h1e NM_015787 HIST1H1E (H1.4) NM_005321 
Histone H1.0 H1f0 NM_008197 H1F0 NM_005318 
Histone H1oo H1foo NM_183811 H1FOO NM_153833 
Histone H1t Hist1h1t NM_010377 HIST1H1T NM_005323 
Histone H1t2 H1fnt NM_027304 H1FNT NM_181788 
Histone H1x H1fx NM_198622 H1FX NM_006026 
Histone Hils1 Hils1 NM_081792 HILS1 AY286318 
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 Incubate for 10 minutes at 25ºC, followed by 50 minutes at 50ºC and 
terminate the reaction at 85ºC for 5 minutes.  
• Each reaction typically yields 100-250 ng/μl of cDNA product. Store cDNA 
products at -20ºC or proceed immediately for real-time quantitative PCR (qPCR).  
4.2.2.3) qPCR can accurately quantify the target sequence copies with high 
efficiency and reproducibility [296]. We choose qPCR measured by SYBR Green 
dye, which gives a fluorescent signal only when it intercalates with double-stranded 
DNA (dsDNA). Although not as specific as Taqman assay [296], this method is more 
cost effective, easier to be adopted in the laboratory, and gives more versatility to 
qPCR. Therefore, it is important to examine the amplification plot (Figure 4.2A) and 
the derivative melting curves of the qPCR product (Figure 4.2B) to ensure reaction 
efficiency and specificity. 
4.2.2.4)  Design forward and reverse PCR primers specific for each H1 gene (Table 
4.1).  Due to the high sequence similarity among somatic H1s, particularly in the 
region corresponding to the central globular domain, it is critical to ensure that the 
primers designed for a specific H1 subtype do not align with other H1 genes, or cross 
amplify other H1 subtypes. It is also important to note that most H1 genes do not 
contain introns. Thus intron-spanning primers that typically adopted for RT-PCR to 
avoid genomic contamination are not available.  Instead, RNA samples should be 
pre-treated with DNase (see 4.2.1.5) to eliminate any trace amount of genomic 
contamination.  In addition, RT(-)-qPCR should be performed in parallel to validate 
the lack of genomic contamination in the cDNA samples.      
4.2.2.5) Also design primers for internal reference genes, whose expression are not 
changed among samples.  Often housekeeping genes, such as glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and beta-actin genes, are chosen as reference 
genes.  qPCR signals of housekeeping genes serve as normalization controls.    
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4.2.2.6) Prepare each PCR reaction (total volume 25 μl) as following:  12.5 μl of 2x 
IQ SYBR Green Supermix (Bio-Rad) (containing dNTPs, 50 U/ml iTaq DNA 
polymerase, 6 mM MgCl2, SYBR Green I and 20 nM fluorescein), 2 μl of 4 ng/μl 
cDNA, 1.25 ul of 10 nM forward/reverse primer mix, and 9.25 μl of ddH2O, and mix 
well in Microseal 96-well PCR plate. Use Microseal 'B' Adhesive Seals (Bio-Rad) to 
ensure that the plate cover is sealed to the plate. Tap or briefly vortex the PCR plate, 
and spin down the reaction mixtures by a short centrifugation.  Place the plate in 
MyIQ Single Color real-time PCR Detection System (Bio-Rad) for qPCR. 
4.2.2.7)  We use the following qPCR conditions: 95ºC for 3 minutes, followed by 40 
cycles of 95ºC for 10 seconds, 60ºC for 20 seconds, 72ºC for 30 seconds.  Examine 
the amplification curves (Figure 4.2A) for PCR efficiency and Ct (Threshold of cycle) 
values.  The threshold line can be automatically set by the IQ5 Optical System 
Software Version 2.0.  
4.2.2.8)  The primer efficiency and optimal cDNA concentration needed can be tested 
by a standard curve assay, in which a serial dilution of genomic DNA is used for 
qPCR and Ct values are plotted against log of template DNA amount.  An optimized 
qPCR assay with primers of high specificity and efficiency will give a linear standard 
curve, with the coefficient of determination (R2)>0.98.  Avoid primers with amplicon 
length longer than 200 bp, which tend to have poor amplification efficiency.  
4.2.2.9)  Because SYBR Green detects any dsDNA, it is critical to perform a melting 
curve run following the qPCR to ensure that the desired amplicon, but not primer 
dimers or contaminants, are amplified and detected. For melt-curve analysis, 
program the qPCR instrument to heat the samples from 55ºC to 95ºC in 0.5ºC 
increments with data collection.  The default setting of melt-curve analysis for MyIQ 
(Bio-Rad) instrument is the following: 95ºC for 1 minute, 55ºC for 1 minute, followed 
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by 81 cycles of 10 seconds at set-point 55ºC, melt curve, + temp 0.5ºC (camera 
collects data at each cycle).   
4.2.2.10)  Since melting temperature (Tm) of dsDNA is dependent on amplicon 
length and GC content, different amplicons will have different Tm(s). Examine the 
derivative melting curves of the qPCR products to confirm the specific melting 
temperature of desired amplicons as well as the lack of noise amplicon peaks (Figure 
4.3B). 
4.2.2.11)  Prepare duplicate or triplicate reactions for each assay for statistical 
analysis. Include negative controls for qRT-PCR, such as RT(-)-qPCR (qPCR with 
RNA as template without reverse transcription) and qPCR with no cDNA, RNA or 
DNA source added in the PCR mix. RT(-)-qPCR can serve as control for potential 
genomic DNA contamination (RT(-) in Figure 4.2 & 4.3).   
4.2.2.12)  Analyze qPCR data with IQ5 Optical System Software Version 2.0 (Bio-
rad).  Normalize the expression values of H1 isoform genes with the expression of 
housekeeping gene (e.g. GAPDH, ß-actin, HPRT) to obtain relative expression levels 
of H1 genes. 
 
4.2.3. Preparation of total histones 
4.2.3.1)  Dissect mouse tissue and rinse it with ice cold PBS. (If not proceed to 
extraction immediately, snap freeze and store the samples as described in step 
4.2.1.2.)   Mince the tissue into pieces with razor blade. Transfer mince to a dounce 
homogenizer (B pestle). Add 10 ml Sucrose Buffer (0.3 M Sucrose, 15 mM NaCl, 10 
mM HEPES [pH 7.9], 2 mM EDTA, 0.5 mM PMSF, Complete mini proteinase inhibitor 




4.2.3.2)  Transfer the homogenates to a 15 ml tube, spin at 500 rpm for 30 seconds 
(centrifuge model: Eppendorf 5810R); carefully transfer the supernatant to a new 
tube (discard the pellet-tissue debris), and centrifuge at 2000 rpm for 5 minutes, to 
pellet cells. Proceed to step 4.2.3.4. 
4.2.3.3)  If histones and chromatin are to be extracted from cells grown in monolayer, 
rinse with PBS, add PBS to the culture dish, and harvest the cells using cell scraper, 
and pellet cells by centrifugation. For cells grown in suspension, pellet cells by 
centrifugation.   
4.2.3.4)  Resuspend the cell pellet in 10 ml Sucrose Buffer supplemented with 0.5% 
NP-40 (per gram starting tissue amount or 108 cells). Transfer the sample to a 
Dounce homogenizer (B pestle) and dounce 10 strokes within 20 minutes incubation. 
At this point, nuclei are obtained. Examine the nuclei quality under a microscope. 
Pellet the nuclei by centrifugation at 2000 rpm for 5 minutes. Discard the 
supernatant. 
4.2.3.5)  Resuspend the nuclei pellet in 3 ml High Salt Buffer (0.35 M KCl, 10 mM 
Tris [pH 7.2], 5 mM MgCl2, 0.5 mM PMSF - add fresh before each use) per 1 g of 
tissue or 108 cells. Transfer the sample to a small Dounce homogenizer (B pestle) 
and homogenize with 5-10 strokes. 
4.2.3.6)  Aliquot the suspension into 3 Eppendorf tubes (1 ml each), incubate on ice 
for 20 minutes, followed by centrifugation at 14,000 rpm for 10 minutes to pellet 
chromatin.  Discard the supernatant. 
4.2.3.7)  Add 0.8 ml 0.2 N H2SO4 to each chromatin pellet.  Use an eppendorf tube 
pestle dounce to grind the pellet well until the pellet is completely dissociated. 
Incubate the samples on a rotating platform at 4ºC overnight. Total histones are 
extracted with this step of acid treatment. 
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4.2.3.8) Centrifuge at 14,000 rpm for 10 minutes. Transfer the supernatant (histone 
extracts) into two Eppendorf tubes (400 ul/tube).  Discard the pellet. Add 2.5 volumes 
(1 ml) of ice cold ethanol to each tube. Keep the samples at -20ºC overnight. 
4.2.3.9)  Centrifuge at 14,000 rpm for 10 minutes to pellet total histones, discard the 
supernatant. Wash the pellet three times with 70% EtOH, leave on bench for 20-30 
minutes to air dry.  Store the dried proteins at -80ºC or dissolve them in ddH2O and 
proceed to HPLC analysis immediately.  Dried proteins can be stored at -80ºC for up 
to 1 year. 
 
4.2.4. HPLC analysis of linker histones 
4.2.4.1)  Resuspend the histone pellet in the recommended volume of ddH20 
depending on the capacity of reverse-phase column and the HPLC instrument. We 
use C18 reverse phase column 250 x 4.6 mm (Vydac) and Äktapurifier UPC 10 
instrument (GE healthcare) for HPLC analysis. We typically dissolve 50-100 μg of 
total histones in 100 μl of ddH20 for analysis.  
4.2.4.2)  Centrifuge at 14,000 rpm for 5 minutes to remove insoluble residues.  
Bradford protein assay is used to determine the amount of protein to be injected onto 
the column. Inject 50-100 μg of total protein into the reverse phase column on HPLC 
system. Loading an excess amount of protein should be avoided to prevent clogging 
of the column. 
4.2.4.3)  Fractionate the linker histones and core histones with an increasing 





Table 4.2: Increasing acetonitrile gradient over time. 
Time (Min.) 
Acetonitrile/ 
0.1% TFA (%) 
0.1% TFA/ddH2O 
(%) 
0 0 100 
1 5 95 
11 25 75 
26 30 70 
45 35 65 
66 40 60 
75 43 57 
126 55 45 
131 90 10 
136 5 95 
 
4.2.4.4)  The effluent is monitored at 214 nm, and the HPLC profiles (Figure 4.4) are 
recorded and analyzed using Äktapurifier UPC 10 (GE Healthcare) with UNICORN 
5.11 software (GE Healthcare). The protein fractions can be also collected with 
fraction auto-collector (Frac-920 - GE) for further analysis, e.g. SDS-PAGE and mass 
spectroscopy. 
4.2.4.5)  The A214 values of the peaks of each H1 subtype and H2B are normalized 
by the number of peptide bonds of each corresponding histone protein. The relative 
proportion of individual H1 histone subtypes within the H1 family, as well as the ratio 
of H1 subtypes to nucleosome core particles can be calculated from these 






4.3. Representative Results 
The list of mammalian H1 subtypes, overall flowchart and representative results 
of the expression analysis of individual histone H1 genes are shown in Table 4.1, 
Figure 4.1 and Figures 4.2-4.5, respectively.  Figure 4.2A shows typical amplification 
curves of H1a qPCR reactions using cDNA prepared from mouse liver and mESCs, 
whereas Figure 4.2B shows the derivative melting curves of the corresponding 
amplicons. The melting curve displays a single characteristic peak at melting 
temperature (Tm) at 860C for the H1a PCR amplicon, and lacks non-specific 
background peaks, suggesting high specificity of H1a qPCR assay.  Evaluation of the 
amplification plot (Figure 4.A) shows that the triplicate qPCR reactions of each 
sample gave consistent signals with almost identical Ct values, suggesting high 
reproducibility.  The lack of amplicons build-up from RT(-)-qPCR reactions indicates 
that genomic DNA contamination was not present, or minimal.   
 
Figure 4.2: Representative results of H1a qPCR assay. A: Amplification plot of H1a qPCR 
assay. The threshold line and Ct values set by the IQ5 Optical System Software are indicated. 
B: Derivative melt-curves of qPCR products shown in (A). 
 
Utilizing the Ct values of H1 genes and housekeeping genes, such as GAPDH, the 
relative RNA expression levels of each H1 gene is calculated. Examples of 
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calculated results for H1.0 and H1a genes are shown in Figure 4.3. The relative 
expression levels of H1a mRNA are higher in mESCs compared with mouse liver, 
whereas H1.0 expression is much higher in liver than in mESCs.   
 
Figure 4.3: qRT-PCR analysis of mRNA levels of H1a and H1.0 in mESCs and adult mouse 
liver.  Y axis represents relative expression levels of H1 genes to that of the reference gene 




The difference in expression of H1a or H1.0 in mESC versus adult mouse liver is also 
evident from HPLC profiles of histone proteins (Figure 4.4).  H1.0, the differentiation 
specific H1, is accumulated to a large amount in mature tissues, accounting for 
27.2% of total H1 in adult liver (Figure 4.5A).  In contrast, H1.0 protein is nearly 
absent in undifferentiated mESCs (Figure 4.4B).  On the other hand, H1a is highly 
expressed, both in mRNA transcripts and proteins, in mESCs (Figure 4.3 & 4.4B).  
Through quantification of H1 peaks in HPLC profile, the relative proportion of each 
individual H1 subtype within the H1 family is determined (Figure 4.5A).  Furthermore, 
the values of individual H1 subtype (or total H1) per nucleosome can be calculated 
by the ratio of the normalized A214 peak value of corresponding H1 subtypes (or 
sum of total H1) to one-half of the normalized A214 values for H2B (Figure 4.5B). 
A





Figure 4.4: HPLC analysis of histones extracted from mammalian cells.  Reverse-phase 
HPLC analysis of 100 μg total histones extracted from adult mouse liver (A) and mouse ESCs 




Figure 4.5: H1 subtype composition and H1 per nucleosome ratios in adult mouse liver.  The 
A214 values of the peak area for each H1 isoform and H2B are calculated using UNICORN 
5.11 software (GE Healthcare), and normalized by the number of peptide bonds present in 
the corresponding histone protein. The sum of normalized A214 values of all H1 subtypes is 
obtained as the value for total H1.  The percentage of total H1 for each H1 subtype (A) as well 
as the ratio of H1 to nucleosome (represented by one-half of the normalized A214 values of 







The set of assays presented here enable comprehensive analysis of the 
expression levels of mammalian linker histone subtypes.  Properly designed qRT-
PCR assays provide highly sensitive and accurate measurements of RNA messages 
from any mammalian histone H1 genes.  The critical part of qRT-PCR assays for 
linker histone subtype genes is the preparation of cDNA using random primer based 
reverse transcription.  mRNA of most histone genes, including most H1 genes, do not 
contain a long poly-A tail presented in other cellular mRNAs. Thus the traditional 
reverse transcription method with oligo-dT primers will not efficiently produce H1 
cDNAs.  Expression analysis of the few H1 genes with mRNA transcripts containing 
poly-A tails, such as H1.0, is equally effective with random hexamers based qRT-
PCR (Figure 4.3), probably due to the high abundance of H1 RNAs. Nevertheless, a 
mixture of oligo-dT primers and the random hexamers for RT reaction can be 
adopted to improve RT efficiency of polyadenylated mRNAs that are of low copy 
numbers, allowing broader coverage of genes analyzed by qRT-PCR.  qRT-PCR of 
internal reference genes, such as housekeeping gene GAPDH, is included so that 
the relative expression level of specific H1 genes across different tissues or cell types 
can be compared (Figure 4.3). By combining qRT-PCR with standard curve analysis, 
it is also possible to obtain absolute copy numbers of H1 cDNAs from various 
samples (data not shown).  
Here we also describe the protocols for histone extraction and HPLC analysis of 
histone proteins. The advantage of this method is that one can determine the relative 
proportions of each H1 subtype within the pool of total H1 proteins as well as quantify 
the ratio of individual H1 subtype (and total H1) per nucleosome.  In addition, 
compared with other protein analysis methods, such as Western blotting, the HPLC 
analysis provides more quantitative and reproducible measurements of all H1 
subtypes.  The different levels and composition of H1 subtypes in the cell modulate 
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chromatin higher order chromatin structure.  The ratio of H1 to nucleosome has been 
shown to correlate with chromatin compaction and is a determinant for nucleosome 
repeat length in chromatin [10]. Thus, the methods we described here should have 
wide applications in chromatin research.   
  
4.5. Table of specific reagents and equipment 
Name of the reagent Company 
Catalogue 
number 
RNase Zap® Applied Biosystems AM9780 
Trizol Reagent Invitrogen 15596-018 
SuperScript III Invitrogen 18080-051 
Absolute Ethanol Fisher Scientific BP2818-4 
IQ SYBR Green Bio-Rad 170-8880 
RNeasy Mini Kit Qiagen 74104 
Deoxyribonuclease I Sigma AMP-D1 
Microseal 96-well PCR plate Bio-Rad MSP-9605 
Microseal 'B' Adhesive Seals Bio-Rad MSB-1001 
Sucrose Agros Organics AC40594 
Sodium phosphate dibasic 
heptahydrate (Na2HPO4·7H2O) 
Fisher Scientific BP332 
Sodium chloride (NaCl) American Bioanalytical AB01915 
Sodium dihydrogen phosphate 
heptahydrate (NaH2PO4·7H2O) 
Fisher Scientific BP-330 
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HEPES Fisher Scientific BP310 
Complete Mini proteinase inhibitor 
cocktail tablet 
Roche Applied Science 11836153001 
EDTA Sigma E-5134 
Phenylmethanesulfonyl fluoride 
(PMSF) 
American Bioanalytical AB01620 
Nonidet-40 (NP-40) American Bioanalytical AB01425 
Potassium chloride (KCl) Fisher Scientific BP366 
Tris [hydroxymethyl aminomethane] American Bioanalytical AB02000 
Magnesium chloride (MgCl2) Fisher Scientific BP214 
Sulfuric acid (H2SO4) VWR VW3648-3 
Ammonium hydroxide (NH4OH) Agros Organics AC42330 
Bradford Protein Assay Bio-Rad 500-0001 
Acetonitrile EMD AX0145-1 
Trifluoroacetic acid (TFA) J.T.Baker 9470-01 
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CHAPTER 5: Conclusions 
 
   
Ovarian cancer is one of the most common women malignancies, leading to 
death in 63% of cases diagnosed.  Despite intensive research searching for new 
therapies and preventive screenings of higher efficiency and specificity, the 5-year 
survival rate of ovarian cancer patients remains low and largely unchanged for the 
past 50 years.   
 Epigenetic mechanisms play an important role in regulating expression of 
genes that are necessary for ovarian cancer progression. Unlike genetic 
modifications, epigenetics does not involve any changes in nucleotide sequence, and 
thus opens great opportunities for therapeutic intervention. DNA methylation, 
posttranslational histone modifications and microRNA expression have all been 
shown to be disregulated in ovarian cancers [177-180,297]. Additionally, the 
advanced stages of ovarian malignancy correlate well with accumulation of 
epigenetic alterations in tumors (reviewed in [298]). Therefore, components or 
inhibitors of epigenetic machineries or factors, such as chromatin modififying 
enzymes, micro-RNAs, are actively tested as potential therapeutic targets for ovarian 
cancer.  
  Linker histone H1, one of the major chromatin structural proteins, is emerging as 
an important epigenetic factor. Previously thought to act as a general repressor, H1 
is now recognized as specific regulator of gene expression from many in vivo studies. 
Although much is known about the biochemical and structural properties of H1 
variants, little is understood regarding the mechanisms of the epigenetic mechanisms 
regulated by H1 variants or the role of H1 in occurrence and progression of diseases, 
such as cancer. In addition, studying H1 subtypes in ovarian cancer seemed to be 
especially relavant, because recent evidence indicated that several genes 
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abnormally expressed in adenocarcinomas might be targeted by linker histone H1 
variants [40,73,206,207].  
Here, we begin to systematically study the role of H1 variants in ovarian cancer.  
Establishing a comprehensive set of quantitative assays for analysis of RNA and 
protein expression levels of individual H1 subtypes in mammalian cells (Chapter 4) 
allowed us to accurately determine the H1 transcript levels in ovarian adenomas and 
adenocarcinoma samples (Chapter 2). Profiling of H1 variants in ovarian tumors 
indicates dramatically different expression pattern of H1 variants in malignant 
adenocarcinomas compared with benign adenomas. H1.1, H1.4, H1.x, and H1.0 are 
downregulated and the total H1 expression level is lower in malignant adenocarcinomas 
compared with benign adenomas, whereas the expression of other H1 variants was not 
significantly altered or even elevated in malignant tumors.  Importantly, we find that H1 
subtype profiling combined with computational cluster analysis can accurately segregate  
adenomas and adenocarcinomas with overall 97% accuracy (Chapter 2). This study 
establishes expression patterns of H1 variants as ovarian cancer biomarkers. 
To determine the functional role of H1 variants in ovarian cancer cells, we initiated a 
program to modulate the levels of individual H1 variants in the OVCAR-3 epithelial 
ovarian cancer cell line and to characterize the effects of over-expressing specific H1 
variants in these cells.  Toward this end, we report the identification of a novel function of 
histone H1.3 in inhibiting ovarian cancer cell growth and colony formation as well as in 
directly suppressing oncogene H19 expression through epigenetic regulation.   
Expressional analysis of OVCAR-3 cells reveals a surprisingly low level of H1.3 protein 
which are often present in abundant amount in adult tissues.  Over-expression of H1.3 
leads to increased doubling time and reduced colony formation of OVCAR-3 cells, as 
well as changes in cell cycle distribution. mRNA microarray analysis revealed many 
genes are affected, with both genes upregulated or downregulated by histone H1.3 over-
expression.  Network and pathway analysis indicate multiple pathways are affected. 
Interestingly, H19 is one of the most dramatically affected genes by H1.3 over-
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expression.  H19 expression was severely repressed in OV-3/H1.3(H) clone, but 
unchanged in cell lines expressing other FLAG-H1 to a comparable level to that of 
FLAG-H1.3.  H19 gene is an oncofetal gene highly over-expressed in ovarian cancer 
cells. While over-expression of H1.3 effectively represses H19 expression, knockdown of 
H1.3 alleviates the repression on H19.  Furthermore, by analyzing DNA methylation, 
H1.3 occupancy and CTCF binding at H19-ICR, we establish an interplay relationship 
among these epigenetic regulations.  Our data suggest that over-expression of H1.3 
leads to its preferential binding at H19 upstream regulatory regions which in turn leads to 
increase DNA methylation and reduced CTCF binding.    
Through this study, we have found, for the first time, a functional role of H1.3 in 
regulating H19 expression and ovarian cancer cell growth.  Additionally, we demonstrate 
a synergistic effect of H1.3 over-expression and H19 knockdown in inhibiting ovarian 
cancer cell proliferation.  These findings may lead to new strategies to ovarian cancer 
therapeutic intervention. It would also be interesting to test if the effect of over-expressed 
H1.3 on H19 regulation also exist in other cancer cells, such as breast cancer cells.  In 
addition, other novel H1 target genes may be identified from these studies.  











CHAPTER 6: Future Studies 
 
 
There are many unresolved questions regarding the role of histone H1 subtypes in 
gene regulation in ovarian cancer. Here, we demonstrated that histone H1.3 directly 
targets H19 gene and represses its expression in OVCAR-3 cells. To date, this 
repression by a specific H1 variant was only thoroughly examined in the ovarian cancer 
cell line. It would be interesting to analyze the effect of H1.3 over-expression on H19 
regulation in other cancers, in which H19 transcript is significantly elevated, such as 
breast, bladder, liver, and testicular cancers.  The H1 variant expression vectors as well 
as the inducible H1.3 shRNA knockdown system established in this study should be 
useful tools for such future studies. These investigations would determine whether H19 
regulation by histone H1.3 is specific for ovarian cancer cells or occurs in other cancer 
models as well.    
In this study, we also find increased levels of DNA methylation as well as depleted 
CTCF binding within the H19 regulatory region as a result of increased H1.3 occupancy 
in H1.3 over-expressing OVCAR-3 cells.  DNA methylation occurring on the H19 
regulatory region could be due to interaction between linker histone H1 variants and 
DNA methyltransferases (DNMTs) which have been shown both in vitro and in 
mouse ESCs ([207], Cao, Ho, and Fan, unpublished observation).  Whether an 
interaction between histone H1.3 and DNMTs exists in OVCAR-3 cells is not clear.  
To test this possibility, nuclear extracts from OVCAR-3, OVCAR-3/V.O. and OV-
3/H1.3(H) cells can be used for Co-Immunoprecipitation (co-IP). Co-
immunoprecipitation with anti-FLAG antibody using OVCAR-3 cell lines over-
expressing other H1 variants can be performed in parallel to determine if the 
specificity among H1 variants in repression H19 is due to their differential binding 
capacities to DNMTs in OVCAR-3.  Given that multiple H1 variants can interact with 
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DNMTs in vitro and in mESCs, these co-IP experiments would provide crucial 
insights as to the specificity of H1 variants under different cellular milieu.  
On the other hand, the sequences of reduced CTCF binding and increased DNA 
methylation in repressing H19 expression under H1.3 over-expression in OVCAR-3 
cells are not determined in this study.  Future studies utilizing shRNA knockdown of 
the level of CTCF expression in OVCAR-3 and OV-3/H1.3(H)  cells followed by 
examination of H19 expression and DNA methylation at H19-ICR could help 
determine if depleted CTCF occupancy acts upstream or downstream of increased 
DNA methylation in regulating H19 expression in these cells.  To facilitate the 
analysis of the sequence of the events as well as to avoid the lethal effects 
associated with dramatic knockdown of CTCF [299,300], an inducible shRNA 
lentiviral system that is well-established in our lab will be employed in such studies.  
Synergistic effects of over-expression of histone H1.3 with downregulation of H19 
transcript in ovarian cancer cells in severe impairment in OVCAR-3 cells’ growth rate 
point to an attractive avenue for potential future therapeutic intervention in ovarian 
cancers.  However, it is not tested whether the effects of H1.3 on impairment of 
OVCAR-3 growth is mainly due to repression of H19.  To investigate this possibility, 
H19 expression vector will be transfected into OV-3/H1.3(H) cell line to obtain OV-
3/H1.3(H)/H19 cells in which H19 transcript level is increased to that comparable to 
OVCAR-3 cells.  The growth curves of OV-3/H1.3(H)/H19 cells will be measured to 
determine if the growth inhibitory effect by H1.3 over-expression is alleviated in these 
cells, which will indicate a “rescue” effect by H19 over-expression in these cells.     
In this study we generated ovarian cancer cell lines with over-expressed individual 
somatic linker histone variants. We mainly concentrated on linker histone H1.3 and its 
role in H19 gene regulation. However, according to microarray results, H1.3 over-
expressed clones contained many genes with expression changed in dose-dependent 
manners when compared with control cell lines. Those genes could be further 
characterized, and new, potentially important networks can be investigated in order to 
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obtain a more comprehensive view of the effect of linker histone H1.3 in ovarian cancer 
cells. Global gene expression changes may be examined in other H1 variants over-
expressed OVCAR-3 cell lines as well. These analyses would identify new target genes 
important in tumorigenesis, and would significantly enrich our knowledge in 
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F' – GACGATGACGACAAGGGATCCACTAG 
    TAACGGCCGCCAGTGTGCTGGAATTCT 































F' - AATCGGCTGTACGTGTGGAAT-5' 
115 





F' - GGTGCAGAATCGGTTGTAGTT-5' 
143 




F' - ACGCTTCCCCTTCTGTCTCAC-5' 
109 




F' - GAGCCACACCACGTCTTCGTA-5' 
107 





F' - TTCCACATCCATCCCAGAGCA-5' 
84 





F' – GGCCAGACATTAACATTCCCA-5' 
101 




F’ - GGGGTCTAGGATCCTTGTGTT-5' 
130 




F’ - GCGGTCTGTGCCCAATTGCCTG-5' 
94 




F’ - GAGCCTGACAGTGCATTTTCC-5' 
110 




F’ - GGGACAGGAGAGCAGAGACTTC-5' 
83 




F’ - GCCACGGAATCAGTTGAAGGT-5' 
120 




F’ - CATTGGTTCGCGAGGGTCATC-5' 
102 




F’ - GGCTTCCCCTTCAGTCTCAC-5' 
173 







F’ - GGCACGGAATTGGTTGTAGTT-5' 
124 





F’ - ATGGCACGGAATTGGTTGTAG-5' 
137 




F’ - CCTTGGGTCTTGGGTGCTGTC-5' 
135 




F’ - CGCGGCCAGCCCTTCCACATC-5' 
147 




F’ - TGACCGACGGACCCACAGCG-5' 
121 





F’ - TCAGACAGGAAAGTGGCCGC-5' 
107 





F’ - AGGAACGTGAGGTCTGAGCC-5' 
101 




F’ - AGGGAGGTGATGGGGCAATG-5' 
118 




F’ - GCCAGGCATTCATCCCGGTCA-5' 
114 




F’ - GGCCTTCCTGGTGAGCGTGTC-5' 
130 




F’ - CTCCATCTGGGCCGGGTGACT-5' 
102 




F’ - CAAACCATCCCCGAGCGAGTG-5' 
113 




F’ - CCCTACAGGCCAATTTGACTT-5' 
119 





F’ - GAGCAGGACGTGTACTCAGG-5' 
180 












F’ - CCCAGCCTAGACCCCCAGCAT-5' 
91 










F - CGCCTCTCGCCTTCTCCTTCAG-5' 
125 


















A.3. Primers used in bisulfite sequencing analysis 
 



























F - GGTGGTAGGAAGGGGTTTTT 
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